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A B S T R A C T
Background
Hepatic encephalopathy is a disorder of brain function as a result of liver failure or portosystemic shunt or both. Both hepatic
encephalopathy (clinically overt) and minimal hepatic encephalopathy (not clinically overt) significantly impair patient’s quality of life
and daily functioning, and represent a significant burden on healthcare resources. Probiotics are live micro-organisms, which when
administered in adequate amounts, may confer a health benefit on the host.
Objectives
To determine the beneficial and harmful eJects of probiotics in any dosage, compared with placebo or no intervention, or with any other
treatment for people with any grade of acute or chronic hepatic encephalopathy. This review did not consider the primary prophylaxis of
hepatic encephalopathy.
Search methods
We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, Science Citation Index Expanded,
conference proceedings, reference lists of included trials, and the World Health Organization International Clinical Trials Registry Platform
until June 2016.
Selection criteria
We included randomised clinical trials that compared probiotics in any dosage with placebo or no intervention, or with any other treatment
in people with hepatic encephalopathy.
Data collection and analysis
We used standard methodological procedures expected by The Cochrane Collaboration. We conducted random-eJects model meta-
analysis due to obvious heterogeneity of participants and interventions. We defined a P value of 0.05 or less as significant. We expressed
dichotomous outcomes as risk ratio (RR) and continuous outcomes as mean diJerence (MD) with 95% confidence intervals (CI).
Main results
We included 21 trials with 1420 participants, of these, 14 were new trials. Fourteen trials compared a probiotic with placebo or no treatment,
and seven trials compared a probiotic with lactulose. The trials used a variety of probiotics; the most commonly used group of probiotic
was VSL#3, a proprietary name for a group of eight probiotics. Duration of administration ranged from 10 days to 180 days. Eight trials
declared their funding source, of which six were independently funded and two were industry funded. The remaining 13 trials did not
disclose their funding source. We classified 19 of the 21 trials at high risk of bias.
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We found no eJect on all-cause mortality when probiotics were compared with placebo or no treatment (7 trials; 404 participants; RR 0.58,
95% CI 0.23 to 1.44; low-quality evidence). No-recovery (as measured by incomplete resolution of symptoms) was lower for participants
treated with probiotic (10 trials; 574 participants; RR 0.67, 95% CI 0.56 to 0.79; moderate-quality evidence). Adverse events were lower
for participants treated with probiotic than with no intervention when considering the development of overt hepatic encephalopathy (10
trials; 585 participants; RR 0.29, 95% CI 0.16 to 0.51; low-quality evidence), but eJects on hospitalisation and change of/or withdrawal from
treatment were uncertain (hospitalisation: 3 trials, 163 participants; RR 0.67, 95% CI 0.11 to 4.00; very low-quality evidence; change of/
or withdrawal from treatment: 9 trials, 551 participants; RR 0.70, 95% CI 0.46 to 1.07; very low-quality evidence). Probiotics may slightly
improve quality of life compared with no intervention (3 trials; 115 participants; results not meta-analysed; low-quality evidence). Plasma
ammonia concentration was lower for participants treated with probiotic (10 trials; 705 participants; MD -8.29 μmol/L, 95% CI -13.17 to
-3.41; low-quality evidence). There were no reports of septicaemia attributable to probiotic in any trial.
When probiotics were compared with lactulose, the eJects on all-cause mortality were uncertain (2 trials; 200 participants; RR 5.00, 95%
CI 0.25 to 102.00; very low-quality evidence); lack of recovery (7 trials; 430 participants; RR 1.01, 95% CI 0.85 to 1.21; very low-quality
evidence); adverse events considering the development of overt hepatic encephalopathy (6 trials; 420 participants; RR 1.17, 95% CI 0.63 to
2.17; very low-quality evidence); hospitalisation (1 trial; 80 participants; RR 0.33, 95% CI 0.04 to 3.07; very low-quality evidence); intolerance
leading to discontinuation (3 trials; 220 participants; RR 0.35, 95% CI 0.08 to 1.43; very low-quality evidence); change of/or withdrawal from
treatment (7 trials; 490 participants; RR 1.27, 95% CI 0.88 to 1.82; very low-quality evidence); quality of life (results not meta-analysed; 1
trial; 69 participants); and plasma ammonia concentration overall (6 trials; 325 participants; MD -2.93 μmol/L, 95% CI -9.36 to 3.50; very
low-quality evidence). There were no reports of septicaemia attributable to probiotic in any trial.
Authors' conclusions
The majority of included trials suJered from a high risk of systematic error (‘bias’) and a high risk of random error (‘play of chance’).
Accordingly, we consider the evidence to be of low quality. Compared with placebo or no intervention, probiotics probably improve
recovery and may lead to improvements in the development of overt hepatic encephalopathy, quality of life, and plasma ammonia
concentrations, but probiotics may lead to little or no diJerence in mortality. Whether probiotics are better than lactulose for hepatic
encephalopathy is uncertain because the quality of the available evidence is very low. High-quality randomised clinical trials with
standardised outcome collection and data reporting are needed to further clarify the true eJicacy of probiotics.
P L A I N   L A N G U A G E   S U M M A R Y
Probiotics for people with hepatic encephalopathy
Why the review is important
Hepatic encephalopathy is a disorder of brain function as a result of liver failure or portosystemic shunt or both. Both hepatic
encephalopathy (clinically overt) and minimal hepatic encephalopathy (not clinically overt) significantly impair patient’s quality of life
and daily functioning and represent a significant burden on healthcare resources. Probiotics are live micro-organisms, which when
administered in adequate amounts may confer a health benefit on the host. We searched and summarised randomised trials about the
benefits and harms of any probiotic in any dosage, compared with placebo or no intervention, or with any other treatment for people with
any grade of acute or chronic hepatic encephalopathy.
Main findings
The evidence is current to June 2016. Of the 21 included trials including 1420 participants, 14 trials compared a probiotic with placebo or
no treatment and seven trials compared a probiotic with lactulose. The treatment duration of the trials ranged from 10 days to 180 days.
Compared with placebo or no intervention, probiotics probably improve recovery and may lead to improvements in the development of
overt hepatic encephalopathy, quality of life, and plasma ammonia concentrations, but may lead to little or no diJerence in mortality.
Probiotics may slightly improve quality of life when compared with no intervention; however, this conclusion is based on three trials with
low-quality evidence. Whether probiotics are better than lactulose for hepatic encephalopathy is uncertain because the quality of the
available evidence was very low. There were no reports of septicaemia attributable to probiotic in any trial. There was no evidence of more
adverse events with probiotics when compared to placebo or lactulose.
Funding
Eight trials declared their funding source, of which six were independently funded and two were industry funded. The remaining 13 trials
did not disclose their funding source.
Limitations of the review
Many of the included trials suJered from a high risk of systematic error (‘bias’) and a high risk of random error (‘play of chance’). Accordingly,
we consider the evidence to be of low quality.
Conclusions
Compared with placebo or no intervention, probiotics probably improve recovery and may lead to improvements in the development
of overt hepatic encephalopathy, quality of life, and plasma ammonia concentrations, but probiotics may lead to little or no diJerence
in mortality. Whether probiotics are better than lactulose for hepatic encephalopathy is uncertain because the quality of the available
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evidence was very low. High-quality randomised clinical trials with standardised outcome collection and data reporting are needed to
further clarify the true eJicacy of probiotics.
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Summary of findings for the main comparison.   Probiotic for people with hepatic encephalopathy
Probiotic versus placebo or no intervention for people with hepatic encephalopathy
Patient or population: people with hepatic encephalopathy
Setting: inpatients
Intervention: probiotic
Comparison: placebo/no intervention
Anticipated absolute effects* (95% CI)Outcomes
Risk with place-
bo/no intervention
Risk with probiotic
Relative ef-
fect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study population
51 per 1000 30 per 1000
(12 to 73)
Moderate
All-cause mortality
(follow-up: 2 weeks to 3
months)
25 per 1000 14 per 1000
(6 to 36)
RR 0.58
(0.23 to 1.44)
404
(7 RCTs)
⊕⊕⊝⊝
LOW 1,2
 
Study population
790 per 1000 529 per 1000
(442 to 624)
Moderate
No-recovery (incom-
plete resolution of clini-
cal symptoms)
(follow-up: 1 month to 3
months)
877 per 1000 588 per 1000
(491 to 693)
RR 0.67
(0.56 to 0.79)
574
(10 RCTs)
⊕⊕⊕⊝
MODERATE 2
 
Study population
168 per 1000 49 per 1000
(27 to 86)
Moderate
Adverse events - Overt
hepatic encephalopathy
(follow-up: 2 weeks to 3
months)
169 per 1000 49 per 1000
RR 0.29
(0.16 to 0.51)
585
(10 RCTs)
⊕⊕⊝⊝
LOW 1,2
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(27 to 86)
Study population
204 per 1000 143 per 1000
(94 to 219)
Moderate
Adverse events - Change
of/or withdrawal from
treatment
(follow-up: 1 month to 3
months)
158 per 1000 111 per 1000
(73 to 169)
RR 0.70
(0.46 to 1.07)
551
(9 RCTs)
⊕⊝⊝⊝
VERY LOW
1,2,3
 
Quality of life
(follow-up: 1 month to 3
months)
— — — 115
(3 RCTs)
⊕⊕⊝⊝
LOW 1,2
 
Plasma ammonia con-
centration (final and
change scores) (μmol/L)
(follow-up: 1 month to 6
months)
— The mean plasma ammonia concentration (final
and change scores) (μmol/L) in the intervention
group was 8.29 fewer (13.17 fewer to 3.41 fewer).
— 705
(10 RCTs)
⊕⊕⊝⊝
LOW 2,3
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised clinical trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.
1Downgraded one level for serious concerns or two levels for very serious concerns of imprecision (based on few events and wide confidence intervals).
2Downgraded one level for serious concerns or two levels for very serious concerns of trials judged as at high risk of bias (most studies at high risk of bias).
3Downgraded one level for serious concerns or two levels for very serious concerns of inconsistency of the outcomes in eJects.
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Setting: inpatients
Intervention: probiotic
Comparison: lactulose
Anticipated absolute effects* (95% CI)Outcomes
Risk with lactulose Risk with probiotic
Relative ef-
fect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study populationAll-cause mortality
(follow-up: 1 month to 2 months) 0 per 1000 0 per 1000
(0 to 0)
RR 5.00
(0.25 to
102.00)
200
(2 RCTs)
⊕⊝⊝⊝
VERY LOW 1,2
 
Study population
521 per 1000 526 per 1000
(443 to 630)
Moderate
No-recovery (incomplete resolution
of clinical symptoms)
(follow-up: 1 month to 3 months)
500 per 1000 505 per 1000
(425 to 605)
RR 1.01
(0.85 to 1.21)
430
(7 RCTs)
⊕⊝⊝⊝
VERY LOW
2,3,4
 
Study population
81 per 1000 95 per 1000
(51 to 177)
Moderate
Adverse events - Overt hepatic en-
cephalopathy
(follow-up: 1 to 3 months)
60 per 1000 70 per 1000
(38 to 129)
RR 1.17
(0.63 to 2.17)
420
(6 RCTs)
⊕⊝⊝⊝
VERY LOW
2,3,4
 
Study population
160 per 1000 203 per 1000
(141 to 291)
Moderate
Adverse events - Change of/or with-
drawal from treatment
(follow-up: 1 month to 3 months)
114 per 1000 145 per 1000
(101 to 208)
RR 1.27
(0.88 to 1.82)
490
(7 RCTs)
⊕⊝⊝⊝
VERY LOW
,2,3,4
 
Quality of life It is uncertain whether probiotics improve quality of life be-
cause the available evidence is of very low quality.
— 69
(1 RCT)
⊕⊝⊝⊝  
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(follow-up: 1 month to 3 months) VERY LOW 1,2
Plasma ammonia concentration (fi-
nal and change scores) (μmol/L)
(follow-up: 1 month to 3 months)
— The mean plasma ammonia con-
centration (final and change scores)
(μmol/L) in the intervention group
was 2.93 fewer (9.36 fewer to 3.5
more).
— 325
(6 RCTs)
⊕⊝⊝⊝
VERY LOW
2,3,4
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised clinical trial; RR: risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different.
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.
1Downgraded one for serious concerns or two levels for very serious concerns of imprecision (small samples, very few events, and wide confidence intervals).
2Downgraded one level for serious concerns or two levels for very serious concerns of trials judged as at high risk of bias (majority of studies at high risk of bias).
3Downgraded one level for serious imprecision (95% CI includes null eJects).
4Downgraded one level for serious concerns or two levels for very serious concerns of inconsistency in results.
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B A C K G R O U N D
Description of the condition
Hepatic encephalopathy (also known as portosystemic
encephalopathy) is a reversible neuropsychiatric disorder seen in
the context of either acute or chronic liver failure or portosystemic
shunting, or both (Ferenci 2002). Hepatic encephalopathy
is characterised by complex cognitive dysfunction, which is
independent of sleep dysfunction or problems with overall
intelligence (Blei 2001). Minimal hepatic encephalopathy is a
milder form of the same condition, which does not have
obvious clinical signs (Stewart 2007; Bajaj 2011). The onset of
hepatic encephalopathy indicates a poor prognostic outcome. It
may also reduce quality of life and level of daily functioning
(Groeneweg 1998; Arguedas 2003). The pathophysiology of hepatic
encephalopathy is still uncertain, but the prevailing assumption
is that diJerent toxins, such as false neurotransmitters, natural
benzodiazepines, short-chain fatty acids, and mercaptans enhance
the negative eJects of ammonia on the level of consciousness
(Butterworth 1987; Blei 2001; Vaquero 2003). Current therapeutic
options include intensive supportive care, identification and
correction of the precipitating causes, tailored dietary restrictions,
non-absorbable disaccharides, L-ornithine L-aspartate, and/or oral
antibiotics (Riordan 1997; Blei 2001; Als-Nielsen 2003; Als-Nielsen
2004a; Als-Nielsen 2004b; Als-Nielsen 2004c; Jiang 2009).
Description of the intervention
Probiotics are live micro-organisms, which when administered
in adequate amounts may confer a health benefit on the host
(Schrezenmeir 2001). However, the dose needed to confer a health
benefit is unknown for many conditions. Probiotics commonly
come from two groups of bacteria, Lactobacillus or Bifidobacterium.
Within each group, there are diJerent species (e.g. Lactobacillus
acidophilus and Bifidobacterium bifidus), and within each species,
diJerent strains (or varieties). A few common probiotics, such
as Saccharomyces boulardii, are yeasts, which are diJerent from
bacteria. Therapeutic eJects may be strain specific, and so caution
must be exerted in generalising results from one species to another.
While probiotics are generally considered safe, adverse events have
been attributed to their use (Besselink 2008).
How the intervention might work
There is some evidence for an alteration in the composition of
the gastrointestinal bacterial flora of people with liver disease
(Rolfe 2000). Modulation of the gut microbiota is an important
aspect of current therapy; the current conventional treatment
option of the broad-spectrum antibiotic rifaxamin is minimally
absorbed and targets gram-negative and gram-positive enteric
bacteria. Similarly, in addition to the osmotic eJect of lactulose,
which encourages removal of toxic metabolic products such as
ammonia, it is also known to have a bifidogenic eJect (De Preter
2006; Bass 2010). Amongst other potential reasons, one rationale
behind the use of probiotics for hepatic encephalopathy is to
reduce the prevalence of harmful ammonia-producing bacteria
in the gastrointestinal system. Probiotics are thought to reduce
blood ammonia levels by several mechanisms including decreasing
bacterial urease activity, decreasing ammonia absorption by
decreasing pH, decreasing intestinal permeability, and improving
nutritional status of gut epithelium (Poh 2012).
Why it is important to do this review
Hepatic encephalopathy significantly impairs patient’s quality of
life and daily functioning, job performance, and overall mortality
(Groeneweg 1998; Arguedas 2003; Stinton 2013). Caring for and
treating patients with hepatic encephalopathy is a significant
burden on the healthcare system. In 2005, hepatic encephalopathy
cost the US healthcare system an estimated USD 4676.7 million,
increasing to USD 7244.7 million in 2009 (Stepanova 2012). Previous
Cochrane Hepato-Biliary Group systematic reviews have only
shown moderate, and in some cases no benefit for current or
proposed therapies for hepatic encephalopathy, which include
non-absorbable disaccharides, oral antibiotics, branched-chain
amino acids, and dopamine (Als-Nielsen 2003; Als-Nielsen 2004a;
Als-Nielsen 2004b; Als-Nielsen 2004c; Junker 2014; Gluud 2015).
Based on a preliminary analysis, it is estimated that the literature
on probiotics in hepatic encephalopathy has doubled since this
systematic review was last published in 2011, hence this update
will improve the evidence base on the use of probiotics in hepatic
encephalopathy.
O B J E C T I V E S
To determine the beneficial and harmful eJects of probiotics in
any dosage, compared with placebo or no intervention or with
any other treatment for people with any grade of acute or chronic
hepatic encephalopathy. This review did not consider the primary
prophylaxis of hepatic encephalopathy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised trials that compared probiotics with
placebo or no intervention, or with any other treatment for
people with hepatic encephalopathy. We applied no restrictions on
language of publication, publication date, or publication status. We
excluded quasi-randomised trials.
Types of participants
Inclusion criteria
We included all people with any grade of acute or chronic hepatic
encephalopathy in connection with acute and chronic liver disease
as well as acute hepatic failure, no matter the aetiology of liver
disease or factors precipitating the hepatic encephalopathy.
Exclusion criteria
We excluded trials with participants in whom a diagnosis of hepatic
encephalopathy was not confirmed, that is where altered mental
status or cognitive function was not confirmed by a standardised
neuropsychological assessment. Where co-interventions such as
medication were being administered, they had to be administered
equally across the relevant intervention groups of the trial so that
fair comparisons could be made.
Types of interventions
Any probiotic at any dose for any duration. Additional co-
interventions were allowed if received by all trial intervention
groups and deemed suJiciently similar across trial groups. Where
synbiotics were used (a combination of a prebiotic and a probiotic;
Probiotics for people with hepatic encephalopathy (Review)
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a prebiotic is a substance that stimulates the growth of probiotics),
the control group must have received a similar prebiotic to
be included in the review, such that across trial groups the
diJerence in intervention(s) was probiotic alone. For example,
where probiotic and lactulose were compared to antibiotic plus
lactulose, the comparison would have been probiotics versus
antibiotic. If a trial compared probiotics and prebiotics versus
prebiotics, the trial would have been considered a probiotic versus
placebo trial, as the diJerence between the two groups would have
been probiotic alone.
Types of outcome measures
We assessed all outcomes at time points reported by the authors,
but, where possible, also summarised at one, two, three, six
months, and one year.
Primary outcomes
1. All-cause mortality: number of participants dead.
2. Number of participants who did not recover from hepatic
encephalopathy (defined as incomplete resolution of clinical
symptoms). We considered an individual to be 'completely
resolved' if he or she was not in a state of hepatic
encephalopathy based on the trial’s definition of hepatic
encephalopathy used in the inclusion process.
3. Adverse events: number and type of adverse events, defined
as participants with any untoward medical occurrence.
We summarised adverse events that led to treatment
discontinuation and those that did not lead to treatment
discontinuation separately. We defined serious adverse events
according to the International Conference on Harmonisation
(ICH) guidelines (ICH-GCP 1997), as any event that led to
death, was life-threatening, required inpatient hospitalisation
or prolongation of existing hospitalisation, resulted in persistent
or significant disability, and any important medical event that
may have jeopardised the patient or required intervention to
prevent it. We considered all other adverse events as non-
serious.
4. Quality of life: as measured by the 36-Item Short Form Health
Survey (SF-36) or other similar validated scales, such as the
Sickness Impact Profile (SIP) (Brazier 1992; Ware 1994).
Secondary outcomes
1. Change of or withdrawal from treatment: number of participants
who changed/withdrew from their allocated treatment regimen.
2. Sepsis: number of participants with one or more episodes of
sepsis (confirmed by a positive blood culture).
3. Change in plasma ammonia concentration.
4. Duration of stay in hospital: measured in days.
Search methods for identification of studies
Electronic searches
For this update, we searched The Cochrane Hepato-Biliary Group
Controlled Trials Register (Gluud 2016), The Cochrane Central
Register of Controlled Trials (CENTRAL) in the Cochrane Library,
MEDLINE Ovid, Embase Ovid, and Science Citation Index Expanded
(Web of Science) (Royle 2003) all on the 14th of June 2016. The
search strategies with the time spans of the searches are given
in Appendix 1. The search filter for randomised trials in MEDLINE
(OvidSP) was created by Lefebvre 2011, and the search filter for
randomised trials in Embase (OvidSP) was created by Sharon 2006.
We also searched the World Health Organization International
Clinical Trial Registry Platform (WHO ICTRP) (www.who.int/ictrp)
for ongoing and unpublished trials up to June 2016 using
an advanced search for the condition 'hepatic encephalopathy'
and intervention 'probiotic', and using an advanced search for
the condition 'hepatic encephalopathy'. As a quality check,
we searched the ClinicalTrials.gov database (clinicaltrials.gov/
ct2/home) in September 2016, even though ClinicalTrials.gov is
included as one of the registers within the WHO ICTRP portal.
Searching other resources
We handsearched the proceedings of three relevant conferences:
1. American Association for the Study of Liver Disease (AASLD)
from 2005 to 2014;
2. European Association for the Study of the Liver (EASL) from 2005
to 2014;
3. Digestive Diseases Week (DDW) from 2005 to 2014,
using the keywords 'hepatic encephalopathy', 'probiotic',
'bifidobacterium', 'lactobacillus', and 'liver disease'.
We identified further trials through reference lists of relevant
articles and by contacting content experts and authors of
included trials. We applied no date or language restrictions. We
translated non-English language articles using Google Translate
(translate.google.com.au/). Mandarin translations were provided
by Sunny Wu.
Data collection and analysis
Selection of studies
Working independently, three review authors conducted trial
selection and data extraction. None of the review authors was
blinded to journal or author names. Disagreements were resolved
by consensus.
Data extraction and management
We extracted the following information using a standardised data
extraction form.
• General information: author(s), title, source, contact address,
year of trial, country of trial, language of publication, year of
publication.• Trial characteristics: design (randomised clinical trial),
randomisation method, manner of recruitment, sampling
method, duration of intervention period, length of follow-up,
reason for and number of dropouts and withdrawals, adverse
events.• Participants: baseline characteristics of participants in
treatment groups such as sex, age, prevalence of comorbidities
(e.g. diabetes), inclusion and exclusion trial criteria.• Trial setting: e.g. inpatient/outpatient department, emergency
department.• Detailed description of both the intervention and the
comparison intervention, type, dose, and duration of
probiotic(s).• Outcomes: specific outcome reported, assessment instrument
used, scoring range where appropriate.
Probiotics for people with hepatic encephalopathy (Review)
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• Any co-interventions.
We entered data into Review Manager 5 soTware and checked the
data for accuracy (RevMan 2011).
Assessment of risk of bias in included studies
We followed the instructions given in the Cochrane Handbook for
Systematic Reviews of Intervention (Higgins 2011) and the Cochrane
Hepato-Biliary Group Module (Gluud 2016). Methodological quality
was defined as the confidence that the design and the report of
the randomised clinical trial would restrict bias in the comparison
of the treatment groups (Moher 1998). According to empirical
evidence (Schulz 1995; Moher 1998; Kjaergard 2001; Wood 2008;
Lundh 2012; Savović 2012; Savović 2012a), we assessed the risk of
bias of the trials using the following 'Risk of bias' domains.
Sequence generation• Low risk of bias: the method used was either adequate
(e.g. computer-generated random numbers, table of random
numbers) or unlikely to introduce bias.• Unclear risk of bias: there was insuJicient information to assess
whether the method used was likely to introduce confounding.• High risk of bias: the method used was not best practise for
randomisation.
Allocation concealment• Low risk of bias: the method used (e.g. central allocation) was
unlikely to induce bias on the final observed eJect.• Unclear risk of bias: there was insuJicient information to assess
whether the method used was likely to induce bias on the
estimate of eJect.• High risk of bias: the method used (e.g. open random allocation
schedule) was likely to induce bias on the final observed eJect.
Blinding of participants• Low risk of bias: blinding was performed adequately, or the
outcome was not likely to be influenced by lack of blinding.• Unclear risk of bias: there was insuJicient information to assess
whether the type of blinding used was likely to induce bias on
the eJect.• High risk of bias: no blinding or incomplete blinding, and the
outcome was likely to be influenced by lack of blinding.
Blinding of personnel• Low risk of bias: blinding was performed adequately, or the
outcome was not likely to be influenced by lack of blinding.• Unclear risk of bias: there was insuJicient information to assess
whether the type of blinding used was likely to induce bias on
the eJect.• High risk of bias: no blinding or incomplete blinding, and the
outcome was likely to be influenced by lack of blinding.
Blinding of outcome assessors• Low risk of bias: blinding was performed adequately, or the
outcome measurement was not likely to be influenced by lack of
blinding.
• Unclear risk of bias: there was insuJicient information to assess
whether the type of blinding used was likely to induce bias on
the estimate of eJect.• High risk of bias: no blinding or incomplete blinding, and the
outcome measurement was likely to be influenced by lack of
blinding.
Incomplete outcome data• Low risk of bias: the underlying reasons for missing data were
unlikely to cause treatment eJects to depart from plausible
values, or appropriate methods were employed to handle
missing data.• Unclear risk of bias: there was insuJicient information to assess
whether the missing-data mechanism in combination with the
method used to handle missing data was likely to induce bias on
the estimate of eJect.• High risk of bias: the crude estimate of eJects (e.g. complete-
case estimate) was clearly biased due to the underlying reasons
for missing data, and the methods used to handle missing data
were unsatisfactory.
Selective outcome reporting• Low risk of bias: the trial protocol was available, or the
study author provided further information about prespecified
outcomes and all of the trial's prespecified outcomes that were
of interest in the review were reported or similar.• Unclear risk of bias: there was insuJicient information to assess
whether the magnitude and direction of the observed eJect
were related to selective outcome reporting.• High risk of bias: not all of the trial's prespecified primary
outcomes were reported or similar.
Other bias• Low risk of bias: the trial was independently funded, e.g. by a
government organisation or university.• Unclear risk of bias: the trial did not declare its funding source.• High risk of bias: the trial was industry funded, e.g. by a
pharmaceutical company, or an author was an employee of a
pharmaceutical company.
We considered trials judged as being at  low risk of bias in  all of
the  specified individual  domains  as trials at low risk of bias. We
considered trials judged as being at unclear risk of bias or high risk
of bias in one or more of the specified individual domains as trials
at high risk of bias. We contacted authors of the original reports
to provide further details when any of the above information was
unclear.
Measures of treatment e8ect
We conducted data analysis according to the guidelines presented
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) and the Cochrane Hepato-Biliary Group Module
(Gluud 2016).
For dichotomous data, we presented results as summary risk
ratio (RR) with 95% confidence intervals (CI). For continuous data,
we presented results as mean diJerence (MD) if outcomes were
measured in the same way amongst trials.
Probiotics for people with hepatic encephalopathy (Review)
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Dealing with missing data
Data for all participants were analysed in the group to which
they are allocated, regardless of whether or not they received the
allocated intervention. If in the original reports participants were
not analysed in the group to which they were randomised and
there was suJicient information in the trial report, we attempted to
restore these participants to the correct group, that is we conducted
intention-to-treat analysis where it was possible to do so. Where
data were missing, we sought clarification from the authors of the
trial. If intention-to-treat analysis was not possible, we conducted
available-case analysis or per-protocol analysis.
Assessment of heterogeneity
We assessed heterogeneity amongst trials, when appropriate, using
the I2 and Cochran Q statistics. Where we detected substantial
heterogeneity (I2 more than 50% or P less than 0.10), we
explored this heterogeneity by prespecified subgroup analysis and
sensitivity analysis.
Assessment of reporting biases
Where we suspected reporting bias, we attempted to contact trial
authors to provide the missing outcome data. When missing data
were thought to potentially introduce serious bias, the impact
of including such trials in the overall assessment of results was
explored by a sensitivity analysis. Where there were at least 10
trials, we also used funnel plot asymmetry to assess the existence
of bias.
Data synthesis
We conducted statistical analysis with random-eJects model meta-
analyses using Review Manager 5 soTware (RevMan 2011). We used
random-eJects models for all analyses where trials examined the
same intervention and the trials populations and methods were
judged to be suJiciently similar. We originally planned to also
conduct fixed-eJect model meta-analysis, but abstained due to
obvious heterogeneity of participants and intervention. We defined
a P value of 0.05 or less as significant.
Subgroup analysis and investigation of heterogeneity
The following were priori subgroup analyses.
• Type of probiotic (by genus): Lactobacillus, Bifidobacteria,
mixed, or unclear.• Grade of hepatic encephalopathy: minimal compared to overt.• Duration of therapy.• MELD (Model for End-Stage Liver Disease) score.
• Co-interventions used.• Trials with low risk of bias compared to trials with high risk of
bias.
We assessed diJerences among subgroups by test of interaction
(Altman 1996).
Sensitivity analysis
We carried out sensitivity analysis when we detected significant
heterogeneity (I2 more than 50% or P less than 0.10) to determine
the source, that we sequentially removed trials from the analysis
to determine which trial or trials were contributing to the
heterogeneity.
'Summary of findings' tables
We used the GRADE system to evaluate the quality of the evidence
for outcomes reported in the review, considering the within-study
risk of bias (methodological quality), inconsistency, imprecision,
indirectness, and publication bias (GRADEpro).
We defined the levels of evidence as 'high', 'moderate', 'low', or 'very
low':
• High certainty: this research provides a very good indication
of the likely eJect; the likelihood that the eJect will be
substantially diJerent is low.• Moderate certainty: this research provides a good indication
of the likely eJect; the likelihood that the eJect will be
substantially diJerent is moderate.• Low certainty: this research provides some indication of the
likely eJect; however, the likelihood that the eJect will be
substantially diJerent is high.• Very low certainty: this research does not provide a reliable
indication of the likely eJect; the likelihood that the eJect will
be substantially diJerent is very high.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The process of identifying reports of randomised clinical trials for
inclusion in the original review and in the review update is outlined
in Figure 1.
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Figure 1.   Study flow diagram.
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The original review published in 2011 included a total of seven trials
reported in nine publications.
In this update, the electronic searches of the Cochrane Hepato-
Biliary Group Controlled Trials Register (n = 13), the Cochrane
Central Register of Controlled Trials (CENTRAL) (n = 58), MEDLINE
(n = 85), Embase (n = 272), and Science Citation Index Expanded
(n = 291) identified a total of 719 publications. We identified six
additional trials from reference list (n = 4) and trials registry (n = 3)
searching.
ATer excluding 188 duplicates and 197 records overlapping with
the original search, 341 unique records remained. Of these, we
excluded 302 aTer reviewing titles and abstracts, and of the
remaining 39 records, which we assessed aTer reviewing their
full texts, we excluded a further 15 records. Three of the 39
records were identified as ongoing trials (ACTRN12610001021066;
IRCT201211012417N9; NCT01798329); therefore, the results were
not available for use in the review; information about these trials is
provided in Characteristics of studies awaiting classification.
Consequently, the review update contributed an additional 14 new
trials reported in 20 publications.
Seventeen reports were of 13 new trials (Loguercio 1995; Qiao
2010; Saji 2011; Dhiman 2013a; Zhao 2013; Zhitai 2013; Ziada
2013; Bajaj 2014a; Lunia 2014; Mouli 2014; Sharma 2014; Shavakhi
2014; Vlachogiannakos 2014). Three reports were of one previously
excluded trial now included aTer we obtained the manuscript from
the author (Nair 2008).
A total of 30 reports (publications and abstracts) of 21 trials
qualified for inclusion in the review (Figure 1).
Four of these 21 trials were available as an abstract across
four diJerent reports (Dhiman 2013a; Zhitai 2013; Lunia 2014;
Vlachogiannakos 2014), whilst 17 of these 21 trials were published
in 26 diJerent reports.
Included studies
Of the 21 included trials, 14 trials compared a probiotic with
placebo or no treatment in 785 participants (Liu 2004; Bajaj 2008;
Nair 2008; Malaguarnera 2010; Qiao 2010; Pereg 2011; Saji 2011;
Dhiman 2013a; Zhitai 2013; Bajaj 2014a; Lunia 2014; Sharma 2014;
Shavakhi 2014; Vlachogiannakos 2014). Three trials compared
a probiotic with lactulose in 200 participants (Loguercio 1987;
Loguercio 1995; Mouli 2014). Four trials compared a probiotic both
with placebo and with lactulose in 435 participants (Sharma 2008;
Mittal 2009; Zhao 2013; Ziada 2013).
The probiotics used in each trial are in Table 1.
Seventeen trials enrolled participants with minimal hepatic
encephalopathy (Liu 2004; Bajaj 2008; Nair 2008; Sharma 2008;
Mittal 2009; Qiao 2010; Pereg 2011; Saji 2011; Dhiman 2013a; Zhao
2013; Ziada 2013; Bajaj 2014a; Lunia 2014; Mouli 2014; Sharma
2014; Shavakhi 2014; Vlachogiannakos 2014), and three trials
enrolled participants with overt hepatic encephalopathy (grade I or
II according to the West Haven criteria) (Loguercio 1987; Loguercio
1995; Malaguarnera 2010). The type of hepatic encephalopathy in
one trial was unclear from the text (Zhitai 2013).
Excluded studies
We excluded a total of 320 newly identified and separate
publications in the update. One previously excluded study was
included aTer a manuscript containing further information was
obtained from the author (Nair 2008).
Risk of bias in included studies
Reporting of trial methodology was incomplete for the majority of
the domains, as summarised in Figure 2 and Figure 3. We classified
most trials at a high risk of bias (with the exception of Bajaj 2014a
and Nair 2008).
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Figure 2.   Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as
percentages across all included trials.
 
 
Probiotics for people with hepatic encephalopathy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
14
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 3.   Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included
trial.
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Figure 3.   (Continued)
 
Allocation
Sequence generation was adequately performed in 12 trials
(Loguercio 1995; Bajaj 2008; Nair 2008; Sharma 2008; Mittal 2009;
Malaguarnera 2010; Saji 2011; Zhao 2013; Bajaj 2014a; Mouli 2014;
Sharma 2014; Shavakhi 2014), inadequately performed in one trial
(Liu 2004), and unclear in eight trials (Loguercio 1987; Qiao 2010;
Pereg 2011; Dhiman 2013a; Zhitai 2013; Ziada 2013; Lunia 2014;
Vlachogiannakos 2014).
Seven trials reported adequate allocation concealment (Loguercio
1995; Liu 2004; Nair 2008; Mittal 2009; Bajaj 2014a; Mouli
2014; Sharma 2014), two trials reported inadequate allocation
concealment (Bajaj 2008; Sharma 2008), and 12 trials were unclear
about their method of allocation concealment (Loguercio 1987;
Malaguarnera 2010; Qiao 2010; Pereg 2011; Saji 2011; Dhiman
2013a; Zhao 2013; Zhitai 2013; Ziada 2013; Lunia 2014; Shavakhi
2014; Vlachogiannakos 2014).
Blinding
Three trials reported adequate blinding of participants, outcome
assessors, and personnel (Loguercio 1987; Nair 2008; Bajaj 2014a).
One trial reported adequate blinding of outcome assessors and
participants, but was unclear regarding blinding of personnel
(Saji 2011). Three trials reported adequate blinding of outcome
assessors, but reported no blinding of participants and personnel
(Bajaj 2008; Ziada 2013; Mouli 2014). One trial was unclear
regarding blinding of outcome assessors, but reported no blinding
of participants and personnel (Shavakhi 2014). One trial reported
blinding of participants, but was unclear regarding blinding of
personnel and outcome assessors (Vlachogiannakos 2014). Three
trials did not blind participants, personnel, or outcome assessors
(Sharma 2008; Mittal 2009; Sharma 2014). The remaining nine trials
were unclear regarding the conduct of blinding (Loguercio 1995; Liu
2004; Malaguarnera 2010; Qiao 2010; Pereg 2011; Dhiman 2013a;
Zhao 2013; Zhitai 2013; Lunia 2014).
Incomplete outcome data
Incomplete outcome data were adequately addressed in six trials
(Bajaj 2008; Nair 2008; Saji 2011; Ziada 2013; Bajaj 2014a; Shavakhi
2014), inadequately addressed in four trials (Loguercio 1987;
Loguercio 1995; Sharma 2008; Pereg 2011), and unclear in the
remaining trials (Liu 2004; Mittal 2009; Malaguarnera 2010; Qiao
2010; Dhiman 2013a; Zhao 2013; Zhitai 2013; Lunia 2014; Mouli
2014; Sharma 2014; Vlachogiannakos 2014).
Selective reporting
Four trials were free of selective outcome reporting (Bajaj 2008;
Sharma 2008; Saji 2011; Mouli 2014), while the remaining 17 trials
were unclear (Loguercio 1987; Loguercio 1995; Liu 2004; Nair 2008;
Mittal 2009; Malaguarnera 2010; Qiao 2010; Pereg 2011; Dhiman
2013a; Zhao 2013; Zhitai 2013; Ziada 2013; Bajaj 2014a; Lunia 2014;
Sharma 2014; Shavakhi 2014; Vlachogiannakos 2014).
Other potential sources of bias
Eight trials declared their funding source (Loguercio 1987; Bajaj
2008; Nair 2008; Pereg 2011; Bajaj 2014a; Mouli 2014; Sharma 2014;
Shavakhi 2014), of which six were independently funded (Bajaj
2008; Nair 2008; Bajaj 2014a; Mouli 2014; Sharma 2014; Shavakhi
2014), and two were industry funded (Loguercio 1987; Pereg
2011). The remaining trials did not disclose their funding source
(Loguercio 1995; Liu 2004; Sharma 2008; Mittal 2009; Malaguarnera
2010; Qiao 2010; Saji 2011; Dhiman 2013a; Zhao 2013; Zhitai 2013;
Ziada 2013; Lunia 2014; Vlachogiannakos 2014).
E8ects of interventions
See: Summary of findings for the main comparison Probiotic
for people with hepatic encephalopathy; Summary of findings 2
Probiotics for people with hepatic encephalopathy
Probiotic versus placebo or no treatment
Primary outcomes
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All-cause mortality
There were no significant diJerences in all-cause mortality
(Analysis 1.1; 7 trials; 404 participants; RR 0.58, 95% CI 0.23 to 1.44;
low quality of evidence).
Number of participants who did not recover from hepatic
encephalopathy
No-recovery (as measured by incomplete resolution of symptoms)
was significantly lower for participants treated with probiotic than
with placebo or no intervention overall (Analysis 1.2; 10 trials; 574
participants; RR 0.67, 95% CI 0.56 to 0.79; moderate quality of
evidence), at one month (Analysis 1.2 (Analysis 1.2.1); 4 trials; 228
participants; RR 0.75, 95% CI 0.58 to 0.96), and at three months
(Analysis 1.2 (Analysis 1.2.3); 3 trials; 229 participants; RR 0.58, 95%
CI 0.43 to 0.78), but not at two months (Analysis 1.2 (Analysis 1.2.2);
3 trials; 117 participants; RR 0.65, 95% CI 0.38 to 1.10).
Adverse events
Adverse events were lower for participants treated with probiotic
than with placebo or no intervention when considering the
development of overt hepatic encephalopathy (Analysis 1.3
(Analysis 1.3.1); 10 trials; 585 participants; RR 0.29, 95% CI 0.16
to 0.51; low quality of evidence), but there were no significant
diJerences for hospitalisation (Analysis 1.3 (Analysis 1.3.3); 3 trials;
163 participants; RR 0.67, 95% CI 0.11 to 4.00; very low quality of
evidence) or change of/or withdrawal from treatment (Analysis 1.3
(Analysis 1.3.5); 9 trials; 551 participants; RR 0.70, 95% CI 0.46 to
1.07; very low quality of evidence).
Quality of life
There were no significant diJerences in quality of life scores for
participants treated with probiotic than with no intervention in the
SF-36 Physical Functioning Scale (Analysis 1.4 (Analysis 1.4.1); 1
trial; 20 participants; MD 0.00, 95% CI -5.47 to 5.47; low quality of
evidence) and the SF-36 Mental Health Scale (Analysis 1.4 (Analysis
1.4.2); 1 trial; 20 participants; MD -4.00, 95% CI -9.82 to 1.82;
low quality of evidence). There was no significant diJerence in
quality of life score for participants treated with probiotic than with
no intervention in the Total Sickness Impact Profile (SIP) Score
(Analysis 1.4 (Analysis 1.4.3); 2 trials; 95 participants; MD -3.66, 95%
CI -7.75 to 0.44; low quality of evidence), but there were significant
diJerences for change in SIP Psychological Score (Analysis 1.4
(Analysis 1.4.4); 2 trials; 95 participants; MD -3.54, 95% CI -4.95 to
-2.12; low quality of evidence) and change in SIP Physical Score
(Analysis 1.4 (Analysis 1.4.5); 2 trials; 95 participants; MD -2.94, 95%
CI -4.44 to -1.44; low quality of evidence). A reduced SIP score
indicates improved quality of life.
Secondary outcomes
Sepsis
There were no reports of septicaemia attributable to probiotic in
any trial.
Change in plasma ammonia concentration
Plasma ammonia concentration was significantly lower for
participants treated with probiotic than with no intervention
overall (Analysis 1.5; 10 trials; 705 participants; MD -8.29 μmol/
L, 95% CI -13.17 to -3.41; low quality of evidence), at one month
(Analysis 1.5 (Analysis 1.5.1); 5 trials; 357 participants; MD -5.55
μmol/L, 95% CI -10.67 to -0.42), at three months (Analysis 1.5
(Analysis 1.5.3); 1 trial; 73 participants; MD -6.79 μmol/L, 95% CI
-10.39 to -3.19), and at six months (Analysis 1.5 (Analysis 1.5.3); 1
trial; 64 participants; MD -31.08 μmol/L, 95% CI -40.50 to -21.66),
but not at two months (Analysis 1.5 (Analysis 1.5.2); 4 trials; 211
participants; MD -5.11 μmol/L, 95% CI -14.56 to 4.34).
Duration of hospital stay: measured in days
No trials reported duration of hospital stay.
Subgroup analysis
We performed subgroup analyses for the outcomes no-recovery
(Analysis 1.2) and plasma ammonia concentration (Analysis
1.5) using the prespecified subgroups (Subgroup analysis and
investigation of heterogeneity). We could not perform subgroup
analyses by MELD score, as most trials did not report this, or by risk
of bias, as we judged most trials at high risk of bias.
No-recovery
We detected no significant diJerences for the following subgroup
analyses: type of probiotic used, test for subgroup diJerences: Chi2
= 0.74, df = 2 (P = 0.69); grade of hepatic encephalopathy, test for
subgroup diJerences: Chi2 = 3.56, df = 1 (P = 0.06); duration of
therapy, test for subgroup diJerences: Chi2 = 1.68, df = 2 (P = 0.43);
co-interventions used, test for subgroup diJerences: Chi2 = 3.57, df
= 2 (P = 0.17) (Table 2).
Plasma ammonia
We detected no significant diJerences for the following subgroup
analyses: type of probiotic used, test for subgroup diJerences: Chi2
= 3.26, df = 3 (P = 0.35); grade of hepatic encephalopathy, test for
subgroup diJerences: Chi2 = 0.03, df = 1 (P = 0.85); duration of
therapy, test for subgroup diJerences: Chi2 = 1.09, df = 2 (P = 0.58);
co-interventions used, test for subgroup diJerences: Chi2 = 4.40, df
= 2 (P = 0.11) (Table 2).
Quality of the evidence
In the analyses comparing probiotic versus placebo or no
intervention (Summary of findings for the main comparison), we
downgraded the quality of the evidence to 'moderate' for the
outcome no-recovery because the included trials were at high
risk of bias. Likewise, we downgraded the quality of the evidence
for the outcomes adverse events -- overt hepatic encephalopathy
and plasma ammonia concentration to low because the included
trials were at high risk of bias and the results were inconsistent.
We downgraded the quality of the evidence for the outcomes all-
cause mortality and adverse events -- change of or withdrawal from
treatment or both -- to very low because the included trials were at
high risk of bias and the results were inconsistent or imprecise, or
both.
Heterogeneity
Heterogeneity was demonstrated for the outcome no-recovery
(Analysis 1.2) (Chi2 = 17.48, df = 9 (P = 0.04); I2 = 48%) and
did not seem attributable to type of probiotic used, grade of
hepatic encephalopathy, duration of therapy, or co-interventions
Probiotics for people with hepatic encephalopathy (Review)
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used. Heterogeneity was demonstrated for the outcome plasma
ammonia concentration (Analysis 1.5) (Chi2 = 47.32, df = 9 (P
< 0.00001); I2 = 81%) and did not seem attributable to type
of probiotic used, grade of hepatic encephalopathy, duration of
therapy, or co-interventions used (Table 2).
Probiotic versus lactulose
Primary outcomes
All-cause mortality
There were no significant diJerences in all-cause mortality
(Analysis 2.1; 2 trials; 200 participants; RR 5.00, 95% CI 0.25 to
102.00; very low quality of evidence).
Number of participants who did not recover from hepatic
encephalopathy
There was no significant diJerence in lack of recovery (Analysis 2.2;
7 trials; 430 participants; RR 1.01, 95% CI 0.85 to 1.21; very low
quality of evidence).
Adverse events
There was no significant diJerence between participants treated
with probiotic and those treated with lactulose for adverse
events when considering the development of overt hepatic
encephalopathy (Analysis 2.3 (Analysis 2.3.1); 6 trials; 420
participants; RR 1.17, 95% CI 0.63 to 2.17; very low quality of
evidence), hospitalisation (Analysis 2.3 (Analysis 2.3.3); 1 trial;
80 participants; RR 0.33, 95% CI 0.04 to 3.07; very low quality
of evidence), intolerance leading to discontinuation (Analysis 2.3
(Analysis 2.3.4); 3 trials; 220 participants; RR 0.35, 95% CI 0.08 to
1.43; very low quality of evidence), or change of/or withdrawal from
treatment (Analysis 2.3 (Analysis 2.3.5); 7 trials; 490 participants; RR
1.27, 95% CI 0.88 to 1.82; very low quality of evidence).
Quality of life
There were no significant diJerences in quality of life scores
between participants treated with probiotic and those treated with
lactulose in change in Total SIP Score (Analysis 2.4 (Analysis 2.4.1);
1 trial; 69 participants; MD 0.65, 95% CI -1.13 to 2.43; very low
quality of evidence); change in SIP Psychological Score (Analysis
2.4 (Analysis 2.4.2); 1 trial; 69 participants; MD 0.48, 95% CI -1.04 to
2.00; very low quality of evidence), or change in SIP Physical Score
(Analysis 2.4 (Analysis 2.4.3); 1 trial; 69 participants; MD 0.38, 95%
CI -0.61 to 1.37; very low quality of evidence).
Secondary outcomes
Sepsis
There were no reports of septicaemia attributable to probiotic in
any trial.
Change in plasma ammonia concentration
There was no significant diJerence in plasma ammonia
concentration overall (Analysis 2.5; 6 trials; 325 participants; MD
-2.93 μmol/L, 95% CI -9.36 to 3.50; very low quality of evidence),
at one month or less (Analysis 2.5 (Analysis 2.5.1); 5 trials; 248
participants; MD -4.30 μmol/L, 95% CI -13.17 to 4.56), or at three
months (Analysis 2.5 (Analysis 2.5.2); 1 trial; 77 participants; MD 1.16
μmol/L, 95% CI -1.96 to 4.28).
Duration of hospital stay: measured in days
No trial reported duration of hospital stay.
Subgroup analysis
We performed subgroup analyses for the outcome plasma
ammonia concentration (Analysis 2.5) using the prespecified
subgroups (Subgroup analysis and investigation of heterogeneity).
We did not perform subgroup analyses by MELD score as this was
not reported in most trials, nor by risk of bias as the majority of the
trials were at high risk of bias.
Plasma ammonia
We detected a significant diJerence for the subgroup analyses on
grade of hepatic encephalopathy, test for subgroup diJerences:
Chi2 = 5.22, df = 1 (P = 0.02); I2 = 80.9%. We detected no significant
diJerence for the subgroup analyses on type of probiotic used, test
for subgroup diJerences: Chi2 = 5.60, df = 3 (P = 0.13) (Table 2).
Quality of the evidence
In the analyses comparing probiotic versus lactulose (Summary of
findings 2), we downgraded the quality of the evidence to very low
for all outcomes due to concerns that the included trials were at
high risk of bias, the results were inconsistent or imprecise or both,
and because a surrogate marker was used for clinically important
outcomes.
Heterogeneity
Heterogeneity was demonstrated for the outcome plasma
ammonia concentration (Analysis 2.5) (Chi2 = 11.87, df = 4 (P = 0.02);
I2 = 66%). Heterogeneity seemed largely attributable to the grade
of hepatic encephalopathy, and it did not seem attributable to the
type of probiotic used (Table 2).
D I S C U S S I O N
Summary of main results
We included 21 trials with a total of 1420 randomised participants.
The trials used a variety of probiotics, although the most commonly
used probiotic was VSL#3, a proprietary name for a group of
eight probiotics. Duration of administration of the experimental
intervention varied from 10 days to 180 days. We classified 19 of 21
trials as having a high risk of bias.
Probiotics may lead to little or no diJerence in mortality from any
cause compared with no treatment. Probiotics probably improve
recovery from hepatic encephalopathy (as measured by resolution
of symptoms) compared with no treatment. Probiotics may prevent
the development of overt hepatic encephalopathy compared with
no treatment. The eJects of probiotics on change of/or withdrawal
from treatment is uncertain because the quality of the evidence
was very low. Quality of life may slightly improve for patients
treated with probiotic than with no intervention. Plasma ammonia
concentration may decrease for patients treated with probiotic
than with no intervention. No trial reported duration of hospital
stay.
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It is uncertain whether probiotics are better than lactulose for the
management of hepatic encephalopathy, because the available
evidence was of very low quality across all outcomes. There were
no reports of septicaemia attributable to probiotic in any trial.
Overall completeness and applicability of evidence
The number of trials and randomised participants included in
this review has substantially increased with this update. However,
data from some trials were only available in abstract form;
outcomes were oTen inconsistently reported; and most trials
were at high risk of bias and included few participants. There is
thus limited evidence for the use of probiotics as a treatment
for people with hepatic encephalopathy. Overall, there is a large
number of trials on probiotic use in cirrhosis (without confirmed
diagnosis of hepatic encephalopathy). We have not considered
trials of primary or secondary prevention using probiotics as
prophylaxis against hepatic encephalopathy in the present review,
which ought to be the subject of another systematic review. Also,
trials on synbiotics should be considered for inclusion in the
future alongside probiotics as a separate subgroup to illustrate
comparative eJicacy.
Quality of the evidence
Although compared to the original 2011 review the quantity of
evidence has increased, the quality of evidence has lagged behind
and is far from optimal. Although there may be emerging evidence
for probiotic use, the quality of evidence for their use is low. Further
randomised clinical trials with improved methodological quality
and outcome data collection and data reporting are required to
fully establish the role of probiotics in hepatic encephalopathy. The
use of tools that quantify the statistical reliability of data across
cumulative meta-analysis such as Trial Sequential Analysis, TSA
2011, ought to be included in future updates (Wetterslev 2008;
Thorlund 2011). We also need to search data-bases of regulatory
authorities for additional trials.
Potential biases in the review process
This systematic review with meta-analysis was undertaken with
broad inclusion criteria to assess the totality of available evidence.
Our literature search was comprehensive and did not exclude
trials based on language of publication or publication status. We
attempted to contact authors wherever trial data and methodology
were unclear. All data extraction and analysis was undertaken by
several authors working independently to minimise bias. Despite
these strengths, there were some limitations: for example, we were
not blinded to authorship during data extraction and 'Risk of bias'
assessment. While we did attempt to contact study authors, we
were not always certain that our messages were received, and we
did not attempt to make any further contact if we received no
response to our initial emails. As stated above, we might have
missed trials by not searching databases of regulatory authorities,
and we did not control risks of random errors.
Agreements and disagreements with other studies or
reviews
A review published in 2011 discusses the eJects of prebiotics,
probiotics, and synbiotics in minimal hepatic encephalopathy
(Shukla 2011a). As our review did not evaluate the combination
of probiotics, prebiotics, and synbiotics, it is not possible to make
direct comparisons between the reviews. Of note, the Shukla 2011a
review was only able to locate two trials of probiotics including
participants with minimal hepatic encephalopathy, compared to
the five trials in the previous version of our review (McGee 2011),
suggesting that we utilised a more sensitive search strategy.
A 2011 meta-analysis found improvement in “clinical and
biochemical parameters in patients with minimal hepatic
encephalopathy” and a “decrease the morbidity of clinical hepatic
encephalopathy” (Tang 2011). However, that study used the time
of Number Connection Test as a surrogate for clinical resolution of
symptoms. In addition, they used a fixed-eJect model, while we
used the random-eJects model in our review.
A 2012 review published a study, Holte 2012, with results largely
similar to the initial 2011 publication of our systematic review and
meta-analysis (McGee 2011).
A meta-analysis published in 2015 included nine randomised
clinical trials comparing probiotic against placebo or no
treatment (Zhao 2015). The authors concluded that probiotics
were “associated with improvement of minimal hepatic
encephalopathy, prophylaxis of overt hepatic encephalopathy,
and reduction of SIP score and severe adverse events”, and our
findings mirror these findings to some extent. They grouped
serious adverse events as any of “minimal hepatic encephalopathy
developing into overt hepatic encephalopathy, hospitalisations,
infections, or unrelated emergency room (ER) visits”. However, we
have separated these adverse events into subgroups, and found
a significant diJerence favouring probiotics only for reducing the
progression to overt hepatic encephalopathy, and not for the other
serious adverse events. Furthermore, we have graded our findings
to reflect the quality of the available evidence and the subsequent
uncertainty around the results. In addition, due to the small sample
sizes involved, random error or chance findings may partly explain
the observed diJerences. Our review did not address the issue of
prophylaxis of hepatic encephalopathy.
Another 2015 meta-analysis of probiotic use in hepatic
encephalopathy included observational data as well as
randomised clinical trials, but found only 14 studies, where
we have included 21 randomised clinical trials (Saab 2015).
Saab and colleagues found that when probiotics were compared
with placebo, there was a significant improvement in minimal
hepatic encephalopathy and decreased progression to overt
hepatic encephalopathy, which is consistent with our findings.
This study also reported no significant diJerence in improvement
of minimal hepatic encephalopathy, hospitalisation rates, or
progression to overt hepatic encephalopathy when probiotics
were compared with lactulose, which is again consistent with our
findings. However, the Saab study noted significantly decreased
hospitalisation rates when probiotics were compared with placebo,
which we did not. This is likely due to bias from their observational
data and incomplete evidence synthesis.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Due to the very low overall quality of the evidence, there
is limited evidence for the use of probiotics compared with
lactulose. Compared with placebo or no intervention, probiotics
probably improve recovery and may lead to improvements in the
development of overt hepatic encephalopathy, quality of life, and
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plasma ammonia concentrations, but may lead to little or no
diJerence in mortality.
Implications for research
Hepatic encephalopathy has a poor clinical outcome and is a
significant burden on the healthcare system. Current treatment
options are of limited eJicacy. Probiotics represent an inexpensive
alternative option; however, their benefits and harms are still
uncertain, and many fundamental questions concerning their
use remain. First, the benefits and harms of probiotics must be
assessed in randomised clinical trials with low risk of systematic
errors ('bias') and low risk of random errors ('play of chance').
Moreover, it is unknown whether all probiotics are of equal
eJectiveness or what dose or duration of probiotic therapy is
necessary for treatment. It is also unknown whether colonisation
though multiple dosing is necessary for benefit or if a single dose
of probiotic suJices (McGee 2010). Future research should take
these factors into account and consider alternative study designs;
for example, factorial trials would allow multiple comparisons
to be made in one trial. Future trials should also adhere
to the International Society for Hepatic Encephalopathy and
Nitrogen Metabolism (ISHEN) consensus statement, which makes
recommendations for trials in people with hepatic encephalopathy
(Bajaj 2011), as well as guidelines for the nomenclature of hepatic
encephalopathy (Vilstrup 2014; Allampati 2015). According to this
new nomenclature, the term 'covert hepatic encephalopathy' is
used to denote either 'minimal hepatic encephalopathy' or 'grade
1 hepatic encephalopathy' as per the West Haven criteria (Conn
1977). As the trials included in this review typically pre-date the
development of this new nomenclature, we have continued to
use the term 'minimal hepatic encephalopathy' where this has
been historically applied by the original study authors to describe
their study group, in order to precisely represent the participants
enrolled in those particular studies. Furthermore, we have used
the term ‘acute hepatic encephalopathy’ in our inclusion criteria as
an inclusive term in order to select a broad range of studies. Any
changes to the inclusion criteria based on the new nomenclature of
‘Type A hepatic encephalopathy’ should be considered for the next
review update. The Human Microbiome Project is one important
initiative that will likely contribute to a better understanding of the
complex relationship between humans and microbes (Turnbaugh
2007).
The high response in the control groups of this review
reflects the natural history of hepatic encephalopathy, with its
spontaneously fluctuating nature and possibility for spontaneous
remission. Future trials should take this into account when
assessing the eJicacy of interventions. It is also important that
those conducting trials also account for the time of day in
which assessments are made. Consideration should be given
to the type of placebo used, for example inactivated probiotic.
All trials should at a minimum assess important outcomes
such as mortality, quality of life, and adverse events. Trials
should also be designed according to Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) Statement
(www.spirit-statement.org/) and reported following the CONSORT
Statement (www.consort-statement.org/).
Future systematic reviews on this topic ought to search also
databases of regulatory authorities. Review authors should also
use, for example, Trial Sequential Analysis to control risks of
random errors.
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Characteristics of included studies [ordered by study ID]
 
Methods Design: a prospective randomised trial with open allocation
A 2:1 randomisation to the treatment arm was performed
Trial duration: 60 days
Treatment duration: 60 days
Participants Setting: outpatient single tertiary centre trial
Country: USA
Age range (years): 44 to 60
Total numbers randomised (group A/group B): 25 (17/8)
Sex (M/F): not stated
Language: English
Stage/severity of hepatic encephalopathy: Child-Pugh score A/B/C: 22/3/0.
Cause of hepatic encephalopathy: non-alcoholic aetiology of cirrhosis.
Inclusions: non-alcoholic participants with cirrhosis with minimal hepatic encephalopathy. Defined by
no alcohol intake within 3 months of the trial and a non-alcoholic aetiology of cirrhosis.
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Exclusions:
• Alcohol use within 3 months.                               • Alcoholic aetiology of cirrhosis.                             • Current psychoactive medication use.                • On current therapy for prevention or treatment of overt hepatic encephalopathy.• Lack of English fluency.• History of overt hepatic encephalopathy.• Antibiotic use within 6 weeks of the trial.• Diabetes mellitus.
Interventions Treatment group (A) probiotic yogurt:
1. Streptococcus thermophilus (log 9 CFU/g on Day 0) for 60 days.
2. Lactobacillus bulgaricus (log 8.7 CFU/g on Day 0) for 60 days.
3. Lactobacillus acidophilus and Lactobacillus casei (log 5.9 CFU/g on Day 0) for 60 days.
4. Bifidobacteria (log 5.2 CFU/g on Day 0) for 60 days.
Participants received 12 ounces of yogurt a day.
The specific probiotic used in this yogurt was Yo-Fast 88 manufactured by Chr-Hansen Inc in Denmark.
Yogurt is manufactured by CC Jersey Crème, Spring Valley, Wisconsin.
Control group (B): no treatment.
Outcomes 1. Minimal hepatic encephalopathy reversal.
2. Overt hepatic encephalopathy development.
3. Adherence.
4. Child-Pugh score.
5. MELD score.
6. SF-36 score.
7. Venous ammonia.
8. IL-6 and TNF-alpha levels.
Notes Contacted Professor JS Bajaj on 14 October 2010, who provided additional information.
Funding source: "The General Clinical Research Center at the Medical College of Wisconsin sponsored
by the NIH supported this study". This study declared the funding source and was deemed to be inde-
pendently funded.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk Adequate sequence generation. A 2:1 randomisation was performed using a
random numbers table.
Allocation concealment High risk The treatment allocation was not concealed from the principal investigator.
Blinding 
Participants
High risk Participants knew whether they were in the treatment group or the control
group.
Blinding 
Personnel
High risk The investigator knew whether a participant was included in the treatment
group or the control group.
Blinding 
Outcome assessors
Low risk The outcome scorer was blinded.
Bajaj 2008  (Continued)
Probiotics for people with hepatic encephalopathy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
38
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Incomplete outcome data 
All outcomes
Low risk 3 out of 17 participants in the treatment group dropped out: 1 died from sepsis
unrelated to the trial on day 67 but did not come to his first visit, and 2 did not
like the taste and dropped out on days 13 and 17, respectively.
2 out of 8 participants in the control group dropped out; they developed OHE
on days 22 and 35.
Primary analysis used an intention-to-treat approach.
Selective outcome report-
ing
Low risk All outcomes mentioned in the methods (minimal hepatic encephalopathy
reversal, overt hepatic encephalopathy development, and adherence) were
described in the results at baseline, after 30 days, and after 60 days. Personal
communication with the author revealed no other outcomes were assessed.
Funding source Low risk The General Clinical Research Center at the Medical College of Wisconsin spon-
sored by the NIH supported this study.
Bajaj 2008  (Continued)
 
 
Methods Design: a parallel randomised trial
Trial duration: 8 weeks
Treatment duration: 8 weeks
Participants Setting: outpatient clinic setting
Country: USA
Age range (years): inclusion criteria 18 to 65 years; mean age (SD) in treatment group 56.3 +/- 9.0, place-
bo group 58.4 +/- 4.3; range not specified
Total numbers randomised (treatment group/placebo group): 37 (18/19)
Sex (M/F): 25/12
Language: English
Stage/severity of hepatic encephalopathy: minimal hepatic encephalopathy, MELD score (mean +/- SD
of intervention, control group: 8.6 +/- 2.2, 8.3 +/- 2.0)
Cause of hepatic encephalopathy: cirrhosis due to HCV, HCV + alcohol, alcohol, NASH, and other causes
Inclusions: "Patients with cirrhosis defined as having histological evidence or evidence with radiolo-
gy and endoscopy of cirrhosis whose disease had been stable for 6 months without specific treatment
changes, and were between the age range 18–65 were included."
Exclusions: "We excluded patients with an unclear diagnosis of cirrhosis, those who had consumed
alcohol within 6 months, those with an upper gastrointestinal bleeding episode or need to be on sys-
temic antibiotics within 6 weeks, those on current or past specific treatment for HE, with hepatocellu-
lar cancer, with yogurt/probiotic consumption within 2 weeks, those with inflammatory bowel disease,
history of pancreatitis, psychoactive medication use (apart from chronic anti-depressants), with a re-
cent absolute neutrophil count <500/mm3 and those with liver transplant."
Interventions Lactobacillus GG AT strain 53103, 3 batches of LGG and placebo were used. Each LGG batch had > 50 bil-
lion CFU/g (51, 61, and 53, respectively), without any other organisms. No live organisms were detected
in the placebo batches.
Outcomes 1. Detection of LGG in stool.
2. Serum and urine metabolomics.
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3. Cognition and QoL.
4. Adverse events and serious adverse event.
Notes This study was carried out under the IND mechanism of Center for Biologics Evaluation and Research
(CBER) of the Food and Drug Administration (FDA) (IND number BB13870).
Contacted Professor JS Bajaj on 14 March 2015, who provided additional information.
Funding source: "JSB received funding from NCCAM, NIH grant U01AT004428 for this trial. No other per-
sonal or funding interests exist. Writing and preparation of this paper was performed by the authors".
This study declared the funding source and was deemed to be independently funded.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk "Subjects were then randomised into placebo or LGG for 4 weeks using blocks
of 4 created by the VCU Investigational Pharmacy using a random sequence
generator."
Allocation concealment Low risk Treatment allocation only available to investigational pharmacy staJ.
Blinding 
Participants
Low risk Participants were blinded.
Blinding 
Personnel
Low risk Personnel were blinded.
Blinding 
Outcome assessors
Low risk Outcome assessors were blinded.
Incomplete outcome data 
All outcomes
Low risk "Thirty-seven patients were randomised. Two patients withdrew consent with-
in the first month due to logistic reasons without any adverse events (both LGG
group). One additional patient had to be scheduled for a splenic arterial em-
bolisation for which he would need antibiotics and narcotics (LGG group) and
was withdrawn before receiving medication. Four patients withdrew due to in-
fections or other contraindications to continuation of the study [one broke her
wrist and needed antibiotics (placebo), one had an asymptomatic urinary tract
infection based on urine collected before randomisation with methicillin-sen-
sitive Staphylococcus aureus (placebo), two were found to have dental issues
within a week of randomisation that needed antibiotics (one placebo and one
LGG)]"
Selective outcome report-
ing
Unclear risk "Blood was collected for MELD score, ammonia, serum albumin and pre-albu-
min, and the dietician met with them to confirm continued adherence on the
prescribed diet. If there were no adverse events requiring discontinuation, the
subjects were re-prescribed their medication for another 4 weeks. The end-of-
drug visit was carried out 4 weeks later (8 weeks after drug initiation) where all
procedures including physical examination, cognitive testing, HRQOL evalu-
ation, dietary assessment, sample (blood, urine, stool) collection and evalua-
tion of adherence and adverse events were performed."
Only information at the end of 8 weeks was reported.
Funding source Low risk "JSB received funding from NCCAM, NIH grant U01AT004428 for this trial. No
other personal or funding interests exist. Writing and preparation of this paper
was performed by the authors."
Bajaj 2014a  (Continued)
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Methods Design: randomised parallel trial/double-blind, randomised, placebo-controlled study
Trial duration: 16 weeks
Treatment duration: 16 weeks
Participants Setting: unspecified
Country: India
Age range (years): 45.5 to 52.5
Total numbers randomised: 80
Sex (M/F): 71/9
Language: unspecified
Stage/severity of hepatic encephalopathy: minimal hepatic encephalopathy
Cause of hepatic encephalopathy: unspecified
Inclusions: cirrhotics with MHE
Exclusions: unspecified
Interventions 40 participants received probiotic (1 sachet of VSL#3 (CD Pharma India Pvt. Ltd, New Delhi), at a dose of
900 billion bacteria daily, and 40 participants received placebo.
Outcomes 1. Reversal of MHE.
2. Figure connection test-A.
3. Digit symbol test.
4. Plasma IL-6.
5. Plasma oxindole.
6. Plasma ammonia.
7. MCS of SF-36 HRQOL.
8. Adverse events/serious adverse event.
Notes Clinical Trials Registry - India /2008/091/000268
Contacted Professor RK Dhiman on 22 December 2014. Awaiting additional information from author.
Funding source: abstract only, unable to assess funding source
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Unclear risk Abstract only, unable to assess
Allocation concealment Unclear risk Abstract only, unable to assess
Blinding 
Participants
Unclear risk Abstract only, unable to assess
Blinding 
Personnel
Unclear risk Abstract only, unable to assess
Blinding Unclear risk Abstract only, unable to assess
Dhiman 2013a 
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Outcome assessors
Incomplete outcome data 
All outcomes
Unclear risk Abstract only, unable to assess
Selective outcome report-
ing
Unclear risk Abstract only, unable to assess
Funding source Unclear risk Abstract only, unable to assess
Dhiman 2013a  (Continued)
 
 
Methods Design: a parallel-group randomised trial
Study duration: unknown
Treatment duration: 30 days
Participants Setting: outpatient
Country: China
Age range (years): 43 to 69
Total numbers randomised (group A/group B/group C): 55 (20/20/15)
Group C was not relevant to our analysis.
Sex (M/F): 53/2
Language: English
Stage/severity of hepatic encephalopathy: Child-Pugh score A/B+C: 8/47
Cause of hepatic encephalopathy: people with cirrhosis and hepatic encephalopathy without known
precipitants of hepatic encephalopathy such as renal impairment, alcohol-related hepatic en-
cephalopathy, complicating hepatocellular carcinoma, etc.
Inclusions:
• Cirrhotic patients with minimal hepatic encephalopathy, without over hepatic encephalopathy.• People who had been abstinent from alcohol for at least 2 months, as corroborated by family members
or caregivers or both.
Exclusions:
• Histological features of alcoholic hepatitis.• A history within the previous 6 weeks of factors including infection, treatment with antibiotics, lactu-
lose or immunomodulatory drugs, and gastrointestinal haemorrhage.• Other causes of reversible hepatic functional decompensation such as drug-related hepatotoxicity
and choledocholithiasis.• Other known precipitants of hepatic encephalopathy, including renal impairment, electrolyte imbal-
ance, and complicating hepatocellular carcinoma.
Interventions Treatment group (A)
Oral supplementation with a synbiotic preparation containing Pediacoccus pentosaceus, Leuconostoc
mesenteroides, Lactobacillus paracasei, and Lactobacillus plantarum (each probiotic at 1010 CFUs/day,
total dose of probiotics in a day: 4 x 1010 CFUs) plus 10 g of bioactive fermentable fibre (2.5 g beta glu-
can, 2.5 g inulin, 2.5 g pectin, 2.5 g resistant starch) for 30 days.
Treatment group (B)
10 g of bioactive fermentable fibre (2.5 g beta glucan, 2.5 g inulin, 2.5 g pectin, 2.5 g resistant starch) for
30 days.
Control group (C)
Placebo (non-fermentable fibre) for 30 days.
Outcomes 1. Faecal pH.
Liu 2004 
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2. Venous ammonia levels.
3. Serum endotoxin levels.
4. Minimal hepatic encephalopathy status.
5. Child-Pugh score.
6. Adverse events.
7. Overt hepatic encephalopathy development.
Notes Contacted Dr Q Liu on 15 October 2010, received no response.
Funding source: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation High risk 1 sachet was randomly drawn from a pool for each participant, which is equiv-
alent to drawing lots. We feel that this does not represent best practise for ran-
domisation, and so have judged this category as high risk of bias according to
our predefined criteria.
Allocation concealment Low risk Sachets were coded and contents unknown to investigators when drawn.
Blinding 
Participants
Unclear risk Not stated for participants
Blinding 
Personnel
Unclear risk Which sachets (A, B, or C) contained the synbiotic, fermentable fibre or non-
fermentable fibre preparations was unknown to the investigators until after
the study had been completed and results had been analysed.
Blinding 
Outcome assessors
Unclear risk Not stated for outcome assessors
Incomplete outcome data 
All outcomes
Unclear risk Unclear from the study
Selective outcome report-
ing
Unclear risk Unclear from the study
Funding source Unclear risk Not stated
Liu 2004  (Continued)
 
 
Methods Design: a parallel-group randomised trial
Study duration: 23 days
Treatment duration: 10 days
Participants Setting: outpatient
Country: Italy
Age range (years): 25 to 68
Total numbers randomised (group A/group B): 40 (20/20)
Sex (M/F): 26/14
Language: English
Stage/severity of hepatic encephalopathy: grade I or II
Cause of hepatic encephalopathy: alcohol, hepatitis, cirrhosis
Inclusions: cirrhotic patients with non-advanced hepatic encephalopathy (grade I or II).
Loguercio 1987 
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Exclusions:
• HE degree > 2.• Alcohol use at the moment of the study.• Mental disorders or benzodiazepine use or both.• Non-compliance.
Interventions Treatment group (A)
Enterococcus lactic acid bacteria strain SF68 (2 capsules, each containing 75 x 106 CFUs, 3 times daily,
for 10 days). Bioflorin is a trade name of Giuliani and is distributed by Gipharmex SpA, Italy.
Control group (B)
30 mL lactulose 4 times daily, for 10 days.
Outcomes 1. Mental state.
2. Bowel function.
3. Presence/absence abdominal pain.
4. Blood ammonia level.
5. Presence/absence meteorism.
6. Reitan's test (Number Connection Test).
7. Adverse events.
Notes Additional information on 'Risk of bias' criteria provided by the author. Contacted Professor C Loguer-
cio on 15 October 2010.
Funding source: "Gipharmex (Milan, Italy) supported this study". This study declared the funding source
and was deemed to be industry funded.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Unclear risk Participants were randomly assigned to a treatment group. No further infor-
mation about randomisation
Allocation concealment Unclear risk Information not provided
Blinding 
Participants
Low risk Participants were blinded.
Blinding 
Personnel
Low risk Personnel were blinded.
Blinding 
Outcome assessors
Low risk The outcome scorer was blinded.
Incomplete outcome data 
All outcomes
High risk All participants completed the treatment period. 5 participants given lactulose
and 4 given Enterococcus SF68 did not arrive for post-treatment follow-up. On
day 15, 2 participants given lactulose were withdrawn from the study because
of marked hyperammonaemia and a worsening of hepatic encephalopathy.
Selective outcome report-
ing
Unclear risk Unclear from study
Funding source High risk Gipharmex (Milan, Italy) supported this study.
Loguercio 1987  (Continued)
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Methods Design: randomised parallel trial
Trial duration: 18 weeks
Treatment duration: 3 periods of 4 weeks
Participants Setting: outpatient setting
Country: Italy
Age range (years): 41 to 76
Total numbers randomised: 40
Sex (M/F): 26/14
Language: unspecified
Stage/severity of hepatic encephalopathy: grade 1 to 2 hepatic encephalopathy
Cause of hepatic encephalopathy: alcoholic/other: 21/19
Inclusions: "Forty patients with cirrhosis, with low grade 1-2 hepatic encephalopathy of the chronic re-
current type and ammonia plasma levels above 59 uM (normal values: < 44 uM) were considered suit-
able for the study."
Exclusions: "Exclusion criteria in the selection of patients included the presence of one of these
pathologies: grade 3-4 hepatic encephalopathy, ascites that needed treatment with furosemide, alco-
hol abuse or recent abstinence (<6 months), liver tumour, and hepatorenal syndrome. We also exclud-
ed patients with severe sight disorders, colour blindness, alterations of the eye fundus and disorders of
the anterior segment."
Interventions Participants entered a 15-day run-in period. 1 group of participants took, after main meals, 2 capsules
containing a total of 150 million Enterococcus faecium strain SF68 3 times a day for 4 weeks; the partici-
pants in the lactulose treatment branch ingested, after main meals, 30 mL (20 g) oral lactulose 3 times
a day for the same time span. The treatment was repeated for three 4-week periods, each separated by
a 2-week wash-out interval. During the 2-week wash-out period participants were treated as during the
run-in period.
Outcomes 1. Arterial ammonia concentration.
2. NCT score.
3. Mental state.
4. Encephalopathy Global Score.
5. Flash evoked visual potentials.
Notes Contacted Professor C Loguercio on 7 June 2015, received no response.
Funding source: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk "After the basal evaluation, the patients enrolled in the study were assigned to
one of two treatments according the Broc Plan computerised randomisation
scheme (kindly provided by the Biometrics Division of Bracco SPA)."
Allocation concealment Low risk Computer randomisation was provided by external providers.
Blinding Unclear risk Unclear from the study
Loguercio 1995 
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Participants
Blinding 
Personnel
Unclear risk Unclear from the study
Blinding 
Outcome assessors
Unclear risk Unclear from the study
Incomplete outcome data 
All outcomes
High risk 21 participants were initially randomised to SF68 and 19 to lactulose group.
"Seven patients in the lactulose group interrupted the treatment: one because
of diarrhoea and fever during the second period, two because of drug intoler-
ance with diarrhoea (one during the second period and one during the third
period), and four because of deterioration of the neurological state (one dur-
ing the first period, two during the first wash-out period, and one during the
second period). Therefore, only 14 patients treated with SF68 and 11 treated
with lactulose completed the study."
Selective outcome report-
ing
Unclear risk Unclear from the study
Funding source Unclear risk Unclear from the study
Loguercio 1995  (Continued)
 
 
Methods Design: parallel randomised trial
Trial duration: mean follow-up of group 1 participants was 38.6 ± 8.80 weeks and group 2 participants
was 34.3 ± 9.8 weeks
Treatment duration: 3 months
Participants Setting: unspecified
Country: India
Age range (years): range unspecified, mean (SD): 46.6 (13.1)
Total numbers randomised: 81
Sex (M/F): 47/28
Language: unspecified
Stage/severity of hepatic encephalopathy: minimal hepatic encephalopathy
Cause of hepatic encephalopathy: unspecified in abstract
Inclusions: unspecified in abstract
Exclusions: unspecified in abstract
Interventions Cirrhotic patients with MHE were divided into: group 1 (probiotics, n = 42, VSL#3) and group 2 (control,
n = 39).
Outcomes All participants underwent psychometric tests, critical flicker frequency, glucose hydrogen breath test
for SIBO and lactulose hydrogen breath test for OCTT.
Primary endpoint was reversal of MHE.
Mortality.
Arterial ammonia.
Lunia 2014 
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Small intestinal bowel overgrowth.
Orocaecal transit time.
Notes Contacted Dr Manish Lunia on 22 December 2014. Awaiting additional information from author.
Funding source: abstract only, unable to assess funding source
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Unclear risk Abstract only, unable to assess
Allocation concealment Unclear risk Abstract only, unable to assess
Blinding 
Participants
Unclear risk Abstract only, unable to assess
Blinding 
Personnel
Unclear risk Abstract only, unable to assess
Blinding 
Outcome assessors
Unclear risk Abstract only, unable to assess
Incomplete outcome data 
All outcomes
Unclear risk Abstract only, unable to assess
Selective outcome report-
ing
Unclear risk Abstract only, unable to assess
Funding source Unclear risk Abstract only, unable to assess
Lunia 2014  (Continued)
 
 
Methods Design: a double-blind, parallel-group randomised trial
Study duration: 2004 to 2007
Treatment duration: 60 days
Participants Setting: inpatient
Country: Italy
Age range (years): not stated
Total numbers randomised (group A/group B): 125 (63/62)
Sex (M/F): 62/63
Language: English
Stage/severity of hepatic encephalopathy: Child-Pugh score A/B/C: 46/59/20
Cause of hepatic encephalopathy: chronic hepatitis and cryptogenic cirrhosis with spontaneous hepat-
ic encephalopathy
Inclusions:
• Chronic hepatitis with spontaneous manifest hepatic encephalopathy (mental state grade I or II ac-
cording to the West Haven criteria) and a Number Collection Test-A performance time > 30 seconds.• Hyperammonaemia (venous ammonia concentration > 50 mmol/L).• Co-operative, hospitalised, adult patients with liver cirrhosis diagnosed by clinical, histological, and
ultrasonographic findings (reduced dimensions of the liver as well as splenomegaly) and oesophageal
varices (stages II or III) observed by endoscopy.
Malaguarnera 2010 
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Exclusions:
• Major complications of portal hypertension, such as gastrointestinal blood loss, hepatorenal syn-
drome, or bacterial peritonitis.• Acute superimposed liver injury.• Other neurological disease and metabolic disorders such as alcoholism, diabetes mellitus, unbal-
anced heart failure and/or respiratory failure or end-stage renal disease.• Severe hepatic encephalopathy (mental state grade III to IV).• Administration of anti-hepatic encephalopathy medications such as neomycin, branched-chain
amino acids.• Any additional precipitating factors such as high protein intake (additional high-protein meals), con-
stipation, or intake of psychostimulants, sedatives, antidepressants, benzodiazepines or benzodi-
azepines antagonists (flumazenil).• Fever, sepsis, or shock were also excluded to avoid variations caused by body temperature.
Interventions Treatment group (A)
Bifidobacterium (subtype not stated) + (FOS) fructo-oligosaccharides for 60 days (dose not stated).
Control group (B)
Lactulose for 60 days (dose not stated).
Note: FOS and lactulose were considered comparable because they are both complex carbohydrates,
which are indigestible to humans but digestible to bacteria. We were unable to locate any efficacy data
comparing FOS to lactulose in people with hepatic encephalopathy.
Outcomes 1. Trail Making Test.
2. Cognitive functions.
3. Grade of hepatic encephalopathy.
4. Child-Pugh score.
Notes Contacted Dr M Malaguarnera on 15 October 2010, received no response.
Funding source: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk Randomisation was based on a computer-generated list.
Allocation concealment Unclear risk Unclear from study
Blinding 
Participants
Unclear risk Stated it was a double-blind trial, but not for whom.
Blinding 
Personnel
Unclear risk Stated it was a double-blind trial, but not for whom.
Blinding 
Outcome assessors
Unclear risk Not stated for outcome assessors
Incomplete outcome data 
All outcomes
Unclear risk Unclear from study
Selective outcome report-
ing
Unclear risk Unclear from study
Funding source Unclear risk Not stated
Malaguarnera 2010  (Continued)
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Methods Design: a parallel randomised trial
Study duration: October 2007 to October 2009
Treatment duration: 3 months
Participants Setting: outpatient
Country: India
Age range (years): 32 to 54
Total numbers randomised (group A/group B/group C/group D): 160 (40/40/40/40)
We did not use group B and D in our analysis, as these were not useful to compare to probiotics.
Sex (M/F): 123/37
Language: English
Stage/severity of hepatic encephalopathy: not stated
Cause of hepatic encephalopathy: cirrhosis due to alcoholic liver disease, hepatitis B, hepatitis C, or
other causes
Inclusions: people with cirrhosis who have minimal hepatic encephalopathy, diagnosed by 2 or more
abnormal (+2SD from the mean) psychometric tests.
Exclusions:
• Overt HE based on detailed neurological examination or history of overt HE in past 6 weeks.• Recent history (< 6 wk) of gastrointestinal bleed.• Active ongoing infection.• Renal impairment with serum creatinine > 1.5 mg %.• Electrolyte impairment (serum sodium < 130 or > 150 meq/dL, serum potassium < 3.0 or > 5.5 meq/dL).• Recent alcohol use (< 6 wk) as reported by the person, recent use of antibiotic, lactulose, or LOLA (<
6 wk), use of psychotropic drugs in last 6 weeks.• TIPS, shunt surgery.• Hepatocellular carcinoma.• Severe comorbidity such as congestive heart failure, pulmonary disease, neurological and psychiatric
problems impairing quality of life, or poor vision precluding neuropsychiatric assessment.
Interventions Control group (A)
No treatment.
Treatment group (B)
30 mL to 60 mL lactulose twice daily for 3 months.
Treatment group (C)
VSL#3 (containing Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifi-
dobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lacto-
bacillus bulgaricus) 110 billion CFUs twice daily for 3 months.
Treatment group (D)
6 g (LOLA) L-ornithine L-aspartate 3 times daily for 3 months.
Outcomes 1. Minimal hepatic encephalopathy recovery.
2. Minimal hepatic encephalopathy improvement.
3. Arterial ammonia level.
4. Development of overt hepatic encephalopathy.
5. Sickness Impact Profile Score (quality of life).
Notes Author provided additional information on 'Risk of bias' criteria. Contacted Professor BC Sharma on 14
October 2010.
Author provided unpublished data.
Mittal 2009 
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Funding source: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk Participants were randomised to 1 of the treatment groups using comput-
er-generated random tables.
Allocation concealment Low risk "The sequences were concealed until a decision to enrol a patient was taken
after assessment for eligibility and after receiving informed consent."
Blinding 
Participants
High risk Different way of administering for every treatment, therefore participants
knew which treatment they had received.
Blinding 
Personnel
High risk Compliance was assessed primarily using pill and bottle count, therefore
blinding was not possible.
Blinding 
Outcome assessors
High risk Compliance was assessed primarily using pill and bottle count, therefore
blinding was not possible.
Incomplete outcome data 
All outcomes
Unclear risk 11 participants were lost to follow-up, 3 from group A, 1 from group B, 3 from
group C, and 4 from group D. During treatment, 7 participants had to be ad-
mitted to the hospital for causes other than overt hepatic encephalopathy. Of
these 7 participants, 2 participants died, 1 each in group A and D.
Primary analysis used an intention-to-treat approach, probably with imputa-
tion.
Selective outcome report-
ing
Unclear risk Unclear from the trial
Funding source Unclear risk Not stated
Mittal 2009  (Continued)
 
 
Methods Design: randomised controlled trial
Trial duration: 2 months
Treatment duration: 2 months
Participants Setting: tertiary care medical centre
Country: India
Age range (years): range unspecified, mean (SD): lactulose group 44.2 (10.4); probiotic group 39.6 (11.4)
Total numbers randomised: 120
Sex (M/F): 110/10
Language: English
Stage/severity of hepatic encephalopathy: minimal hepatic encephalopathy; CTP (A/B/C): probiotics
group (14/24/22); lactulose group (15/30/15)
Cause of hepatic encephalopathy: alcoholic/viral/other: probiotics group (24/24/12); lactulose group
(21/24/15)
Mouli 2014 
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Inclusions: The inclusion criterion was the diagnosis of MHE in people with cirrhosis aged between 15
and 80 years.
Exclusions: "The exclusion criteria were: history of overt HE in the past 6 weeks; history of intake of lac-
tulose or probiotics or antibiotics within the past 6 weeks; presence of any other neurological or psy-
chiatric diseases; history of undergoing shunt surgery or transjugular intrahepatic portosystemic shunt
for portal hypertension; currently on medications which were likely to interfere with psychometric
performance; history of alcohol intake during the past 6 weeks; history of gastrointestinal bleeding or
spontaneous bacterial peritonitis in the past 6 weeks; presence of hepatocellular carcinoma, renal fail-
ure or portal vein thrombosis; presence of significant co-morbidities such as diabetes, congestive heart
failure, chronic respiratory disease, chronic kidney disease or malignancy; and visual impairment and
refusal for consent."
Interventions Participants were randomised to receive either lactulose (Lark Laboratories; Rajasthan, India) or pro-
biotics (VSL#3; Sun Pharmaceutical, Mumbai, India) for a period of 2 months. Lactulose was given at a
dose of 30 to 60 mL/day orally to ensure 2 to 3 soT stools per day. VSL#3 was given at a dose of 4 cap-
sules (2 twice a day) per day, amounting to a total of 450 billion CFU/day; each capsule contained 112.5
billion viable lyophilised bacteria of 4 strains of Lactobacillus (L acidophilus DSM 24735, L plantarum
DSM 24730, L paracasei DSM 24733, L delbrueckii subsp. bulgaricus DSM 24734), 3 strains of Bifidobac-
terium (B longum DSM 24736, B breve DSM 24732, B infantis DSM 24737), and 1 strain of Streptococcus (S
thermophilus DSM 24731).
Outcomes The primary outcome measure was improvement of MHE, which was defined as the normalisation of
the prior abnormal neuropsychometric/neurophysiological tests. The secondary outcome measure
was change in venous ammonia level with study intervention. The study endpoints were: (i) completion
of 2 months of treatment; (ii) development of overt HE; and (iii) death.
Notes Trial ID: NCT01008293
Contacted Dr VP Mouli on 14 March 2015, received no response.
Funding source: "We thank the Indian Council of Medical Research (ICMR) for providing a research grant
and CD Pharmaceuticals India for providing probiotic VSL#3 and lactulose". This study declared the
funding source and was deemed to be independently funded.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk "Block randomization was used to allocate the patients to lactulose and probi-
otics groups. The random numbers were generated using Stata software (Stat-
aCorp, College Station, TX, USA)."
Allocation concealment Low risk "Allocation of the patients to receive the study intervention drugs was done by
using the sequentially numbered, opaque, sealed envelope method. The en-
velopes were prepared by a statistician not associated with the conduct of the
study, and were opened sequentially only after the patient’s name, age and
sex were written on them by a person not associated with the study."
Blinding 
Participants
High risk The study was limited by being an open-label trial with a relatively small sam-
ple size with a short period of intervention. Blinding was not possible due to
the differences in physical state between the drugs.
Blinding 
Personnel
High risk The study was limited by being an open-label trial with a relatively small sam-
ple size with a short period of intervention. Blinding was not possible due to
the differences in physical state between the drugs.
Blinding 
Outcome assessors
Low risk The objective nature of the tests for MHE would likely limit the effect of bias on
MHE recovery outcomes and venous ammonia.
Mouli 2014  (Continued)
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Incomplete outcome data 
All outcomes
Unclear risk "60 patients each were randomized into the lactulose and probiotics groups.
Four patients were dropouts and 19 were lost to follow up, two patients died
and 22 developed overt encephalopathy, and hence discontinued with the tri-
al drugs due to different management protocols for overt HE. At the end of in-
tervention (i.e. at 2 months), 40 patients in the lactulose group and 33 patients
in the probiotics group were taken for analysis who had completed the study
medications."
Selective outcome report-
ing
Low risk Outcomes were reported as per protocol found registered at ClinicalTrials.gov
identifier NCT01008293.
Funding source Low risk "We thank the Indian Council of Medical Research (ICMR) for providing a re-
search grant and CD Pharmaceuticals India for providing probiotic VSL#3 and
lactulose".
Mouli 2014  (Continued)
 
 
Methods Design: randomised controlled trial
Trial duration: September 2006 to March 2007 (7 months)
Treatment duration: 4 weeks
Participants Setting: Study was conducted in Department of Neurology, Medical College Calicut, in collaboration
with Department of Gastroenterology.
Country: India
Age range (years): range unspecified, mean 49.5 ± 8.05 SD
Total numbers randomised: 40
Sex (M/F): M:F ratio 1:0.05
Language: English
Stage/severity of hepatic encephalopathy: MHE (Child A 14, Child B 26)
Cause of hepatic encephalopathy: alcohol 29, cryptogenic 10, HBV-related 1
Inclusions:
• Cirrhosis diagnosed by clinical/USG/biopsy.• Minimal hepatic encephalopathy diagnosed by Number Connection Test-A and evoked response tests
- auditory and visual.
Exclusions:
• Clinically evident hepatic encephalopathy.• Neurological diseases.• Alcohol-free period of less than 2 months.• Coexistent gastrointestinal haemorrhage.• Renal impairment and electrolyte disturbances.• Severe visual or auditory abnormalities.
Interventions Group A was given probiotic preparation in a dose of 1-gram sachet containing not less than 1.25 bil-
lion cells of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, and Saccha-
Nair 2008 
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romyces boulardii 3 times daily after meals, and group B was given placebo powder in identically look-
ing sachet in a similar dose.
Outcomes Number Connection Test-A, arterial ammonia, auditory evoked response tests, visual evoked response
tests
Notes Contacted Dr R Nair on 22 December 2014, full manuscript provided, awaiting additional information
from author.
Funding source: "Sachets of drug as well as placebo were supplied by Aristo pharmaceuticals Pvt. Ltd.
No financial aid of any form was received from any source for the purpose of conducting this trial". This
study declared the funding source and was deemed to be independently funded.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk Randomisation was done using random table allocation.
Allocation concealment Low risk Treatment allocation was concealed from individual who did the allocation.
Blinding 
Participants
Low risk "The patients, examiners and investigators were blinded as to who is receiving
the drug and who receives placebo".
Blinding 
Personnel
Low risk "The patients, examiners and investigators were blinded as to who is receiving
the drug and who receives placebo".
Blinding 
Outcome assessors
Low risk "The patients, examiners and investigators were blinded as to who is receiving
the drug and who receives placebo".
Incomplete outcome data 
All outcomes
Low risk 1 dropout in group A and 2 dropouts in group B;
"There were 3 drop outs (Group A - 1, Group B - 2) – one in group A was lost to
follow up, so was one in group B. Second patient in Group B decided to with-
draw from study due to personal reasons."
Selective outcome report-
ing
Unclear risk Unable to assess
Funding source Low risk Sachets of drug as well as placebo were supplied by Aristo Pharmaceuticals
Pvt. Ltd.
No financial aid of any form was received from any source for the purpose of
conducting this trial.
Nair 2008  (Continued)
 
 
Methods Design: a parallel randomised trial
Study duration: unclear
Treatment duration: 6 months
Participants Setting: outpatient
Country: Israel
Age range (years): 53 to 74
Total numbers randomised (group A/group B): 40 (20/20)
Sex (M/F): unclear
Language: English
Pereg 2011 
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Stage/severity of hepatic encephalopathy: minimal hepatic encephalopathy
Cause of hepatic encephalopathy: cirrhosis due to alcoholic liver disease, hepatitis B, hepatitis C, or
other causes
Inclusions: people with liver cirrhosis and at least 1 major complication of cirrhosis in the past, clinical
evidence of portal hypertension, or decreased hepatic synthetic function.
Exclusions:
• Any sign of decompensation from any precipitant including gastrointestinal bleeding, infections,
acute renal failure, electrolyte impairment, or hepatocellular carcinoma.• Those chronically treated with antibiotics or lactulose.• People with alcoholic cirrhosis, for whom alcohol abstinence for at least 2 months prior to enrolment
could not be confirmed.
Interventions Control group (A)
Wheat-based non-fermentable fiber placebo.
Treatment group (B)
Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium bifidum, and Streptococcus ther-
mophilus (Bio Plus, Supherb, Israel), each at a daily dose of 2 x 1010 CFUs.
Outcomes 1. Plasma ammonia.
2. Adverse events.
Notes The study was registered in ClinicalTrials.gov (ID: NCT00312910).
Funding source: "Supported by Supherb Ltd, Israel". This study declared the funding source and was
deemed to be industry funded.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Unclear risk Not stated
Allocation concealment Unclear risk Not stated
Blinding 
Participants
Unclear risk Only stated in the title that the trial was double-blinded - no specific details
provided on who was blinded or how blinding was conducted.
Blinding 
Personnel
Unclear risk Only stated in the title that the trial was double-blinded - no specific details
provided on who was blinded or how blinding was conducted.
Blinding 
Outcome assessors
Unclear risk Only stated in the title that the trial was double-blinded - no specific details
provided on who was blinded or how blinding was conducted.
Incomplete outcome data 
All outcomes
High risk Four participants "dropped out", no further details provided.
Selective outcome report-
ing
Unclear risk Unclear from the trial
Funding source High risk Supported by Supherb Ltd, Israel.
Pereg 2011  (Continued)
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Methods Design: randomised controlled trial
Trial duration: There was a follow-up every 1to 2 weeks until treatment ended in which the incidence of
hepatic encephalopathy was recorded.
Treatment duration: Treatment lasted for 24 weeks, and there was a follow-up every 1 to 2 weeks until
treatment ended in which the incidence of hepatic encephalopathy was recorded.
Participants Setting: Laiyang Central Hospital, Yantai
Country: China
Age range (years): age range from 37 to 70, average age was 53.4
Total numbers randomised: 64
Sex (M/F): of the 64 participants, 51 were male and 13 were female
Language: Mandarin
Stage/severity of hepatic encephalopathy: diagnosed with subclinical hepatic encephalopathy (SHE)
and recruited for this study after intelligence testing
Cause of hepatic encephalopathy: 54 cases were cirrhosis from hepatitis B, 6 cases were alcoholic cir-
rhosis, 1 case was primary biliary cirrhosis, 1 case was Budd-Chiari syndrome, and 2 cases were of un-
known cause.
Inclusions: "Inclusion criteria: between August 2004 and August 2008, of all the patients diagnosed with
cirrhosis, 64 of them we diagnosed with SHE and recruited for this study after intelligence testing. Cir-
rhosis diagnosis was based on history, clinical assessment, laboratory findings, ultrasound, and CT
scan investigations."
Exclusions: "Exclusion criteria:
1. Currently or previously diagnosed with hepatic encephalopathy.
2. Patients with psychological or neurological disease.
3. Use of any sedatives or CNS depressants in the past 4 weeks.
4. Any GI bleeding, electrolyte/acid-base disturbances in the past 2 weeks.
5. Patients with alcoholic cirrhosis and continue to drink alcohol."
Interventions Control group was given compound vitamin B tablets, 2 tablets each time, 3 times a day. Treatment
group was given bifid triple viable, 2 tablets each time, 3 times a day.
Outcomes Outcome measurements: Blood ammonium, ALT, and NCT were measured 1 day before treatment and
again 1 day after treatment. NCT used the NCT-A version, where the patient orders the numbers 1 to 25
and the time it takes to complete the test is recorded, including time spent correcting any mistakes.
NCT was measured in seconds; longer time to complete indicates abnormality.
Notes We could not find author contact details.
Funding source: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Unclear risk Unclear from the trial
Allocation concealment Unclear risk Unclear from the trial
Blinding Unclear risk Unclear from the trial
Qiao 2010 
Probiotics for people with hepatic encephalopathy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
55
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Participants
Blinding 
Personnel
Unclear risk Unclear from the trial
Blinding 
Outcome assessors
Unclear risk Unclear from the trial
Incomplete outcome data 
All outcomes
Unclear risk Unclear from the trial
Selective outcome report-
ing
Unclear risk Unclear from the trial
Funding source Unclear risk Unclear from the trial
Qiao 2010  (Continued)
 
 
Methods Design: a parallel randomised trial/randomised double-blind, placebo-controlled trial
Trial duration: 4 weeks
Treatment duration: 4 weeks
Participants Setting: unclear
Country: India
Age range (years): range unclear, mean age (SD) treatment group/placebo group: 50.6 (5.81)/52.15
(0.18)
Total numbers randomised: total (probiotic/placebo): 43 (21/22)
Sex (M/F): 37/3 excluding dropouts
Language: unspecified
Stage/severity of hepatic encephalopathy: stable cirrhotics in Child’s grade A and B (diagnosed clinical-
ly, by ultrasonography or biopsy) with minimal hepatic encephalopathy diagnosed by NCT and evoked
responses
Cause of hepatic encephalopathy: Aetiology of cirrhosis was alcohol in the majority of participants
(34/40). Other causes included hepatitis B in 2 participants, hepatitis C in 1 participant, and cryptogenic
in 3 participants.
Inclusions: Stable cirrhotics in Child’s grade A and B (diagnosed clinically, by ultrasonography or biop-
sy) and having minimal hepatic encephalopathy as per the NCT-A and evoked responses (auditory and
visual) were included.
Exclusions: "Those with clinically evident hepatic encephalopathy, neurological disease, alcohol free
period of less than 2 months, coexistent gastrointestinal hemorrhage, renal impairment, electrolyte
disturbances and those with severe visual or auditory abnormalities were excluded from the study."
Interventions Group A received probiotic preparation in a dose of 1-gram sachet containing not less than 1.25 bil-
lion spores of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, and Saccha-
romyces boulardii, 3 times daily after meals. Group B received placebo powder in identical-looking sa-
chet 3 times daily after meals. The duration of treatment was 4 weeks.
Saji 2011 
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Outcomes At the end of 4 weeks, participants' symptoms were recorded and a thorough examination was done
for any features of overt encephalopathy. Investigations were done to reassess the Child’s score. Arteri-
al ammonia, NCT –A, and evoked responses were repeated.
Notes Both sachets of probiotics and placebo were supplied by Aristo Pharmaceuticals Pvt. Ltd Mumbai.
Contacted Dr S Saji on 14 March 2015, awaiting additional information from author.
Funding source: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk "Randomization was done using random table allocation."
Allocation concealment Unclear risk Unclear from study
Blinding 
Participants
Low risk "Group B received placebo powder in identical looking sachet".
Blinding 
Personnel
Unclear risk "The patients were randomized to two groups and the drugs were adminis-
tered in a double blind fashion."
Blinding 
Outcome assessors
Low risk Unclear from study, although the objective nature of the tests for MHE would
likely limit the effect of bias on MHE recovery outcomes and venous ammonia.
Incomplete outcome data 
All outcomes
Low risk "There were 3 drop-outs, one in the probiotic group and two in the placebo
group."
"The data reported are only for the intent-to-treat population."
Selective outcome report-
ing
Low risk "At the end of 4 weeks patients symptoms were recorded and a thorough ex-
amination was done for any features of overt encephalopathy. Investigations
were done to reassess the Child’s score. Arterial ammonia, number connection
test–A and evoked responses were repeated."
All of the above outcomes except the Child's score were reported.
Funding source Unclear risk "Sachets of probiotics as well as placebo were supplied by Aristo pharmaceuti-
cals Pvt. Ltd Mumbai."
Saji 2011  (Continued)
 
 
Methods Design: open-label randomised trial
Treatment duration: 1 month
Time period: February 2005 to August 2006
Participants Setting: India
Age range (years): 30 to 54
Total numbers randomised (group A/group B/group C): 105 (35/35/35)
Sex (M/F): 79/26
Language: English
Stage/severity of hepatic encephalopathy: Child-Pugh score A/B/C: 36/39/30
Cause of hepatic encephalopathy: cirrhosis due to alcohol consumption, chronic hepatitis, and crypto-
genic cirrhosis.
Sharma 2008 
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Inclusions: cirrhotic patients with minimal hepatic encephalopathy without overt encephalopathy.
Exclusions:
• The presence of overt hepatic encephalopathy or history of hepatic encephalopathy.• History of taking lactulose or any antibiotics.• Alcohol intake.                        • Gastrointestinal haemorrhage or spontaneous bacterial peritonitis during the past 6 weeks.• Earlier transjugular intrahepatic portosystemic shunt or shunt surgery.• Significant comorbid illness such as heart failure, respiratory failure, or renal failure.• Any neurologic diseases such as Alzheimer’s disease, Parkinson’s disease, and non-hepatic metabolic
encephalopathies.• Colour blindness and mature cataract, diabetic retinopathy, and people on psychoactive drugs such
as antidepressants or sedatives.
Interventions Control group (A)
30 mL to 60 mL lactulose/day for 1 month.
Treatment group (B)
1 capsule (containing Enterococcus faecalis, Clostridium butyricum, Bacillus mesentericus, Lactic acid
Bacillus) 3 times daily for 1 month, dose not stated.
Treatment group (C)
30 mL to 60 mL lactulose plus probiotics daily for 1 month.
Outcomes 1. Venous ammonia level.
2. Child-Pugh score.
3. Minimal hepatic encephalopathy recovery.
Notes Additional information provided by the author. Contacted Professor BC Sharma on 14 October 2010.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk Participants were randomised according to a computer-generated randomisa-
tion chart.
Allocation concealment High risk Trial personnel were able to view the allocation sequence.
Blinding 
Participants
High risk The trial was not blinded.
Blinding 
Personnel
High risk The trial was not blinded.
Blinding 
Outcome assessors
High risk The trial was not blinded.
Incomplete outcome data 
All outcomes
High risk 13 participants in the control group and 5 participants in the lactulose plus
probiotic group were lost to follow-up. Reasons are unclear.
Selective outcome report-
ing
Low risk All outcomes reported in the methods (psychometric tests outcomes, P300 au-
ditory event-related potential, venous ammonia level, and Child-Pugh classifi-
cation) were measured and discussed on baseline and after 1 month. Person-
al communication with the author revealed that no other outcomes were as-
sessed.
Sharma 2008  (Continued)
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Funding source Unclear risk Not stated
Sharma 2008  (Continued)
 
 
Methods Design: a randomised parallel study
Trial duration: 2 months
Treatment duration: Duration of the treatment was 2 months ± 3 days, or unless the participant devel-
oped overt encephalopathy, expired, or was lost to follow‑up.
Participants Setting: Department of Gastroenterology at a teaching hospital
Country: India
Age range (years): range unspecified, mean (SD): 39.1 (12.8)
Total numbers randomised: 124
Sex (M/F): 77/47
Language: unspecified
Stage/severity of hepatic encephalopathy: minimal hepatic encephalopathy by psychometric tests
(NCT‑A, FCT‑A, and DST) and critical flicker frequency (CFF); CTP A/B/C: 35/52/37
Cause of hepatic encephalopathy: anti-HCV positive/HBsAg positive/history of ethanol: 17/30/34
Inclusions: A total of 317 cirrhotics were screened; 111 were excluded, and the remaining 206 cirrhotics
were screened for MHE using NPTs or CFF test or both.
Exclusions: The exclusion criteria included:
• People with overt HE or a history of overt HE in the past 6 weeks.• History of alcohol intake during past 6 weeks.• History of antibiotic or lactulose or probiotics use within the past 3 weeks.• Gastrointestinal bleed in the past 6 weeks.• History of recent use of drugs (< 6 weeks) affecting psychometric performance such as antidepres-
sants, antiepileptic, sedatives, psychotropic drugs.• Spontaneous bacterial peritonitis or other infection in the past 7 days.• Renal insufficiency with creatinine > 1.5 mg/dL.• Electrolyte imbalance.• Hepatocellular carcinoma.• Significant comorbid illness, such as heart, respiratory, or renal failure; and any neurological disease
that could interfere with intellect or motor performance of the person such as Alzheimer’s or Parkin-
son’s disease, respectively, or non-hepatic metabolic encephalopathies.• Previous transjugular intrahepatic portosystemic shunt or shunt surgery.• People who restarted alcohol consumption during follow-up.• Inability to do psychometric tests due to poor vision, or those having colour blindness.• People not having a fair knowledge of numbers and not having been to school for at least 2 years.• Women who were pregnant.
Interventions After the diagnosis of MHE was made, the participants were randomised into 4 groups: DRUG 1 (l-or-
nithine l-aspartate (LOLA), 2 sachets 3 g each thrice a day) n = 31, DRUG 2 (tab rifaximin 400 mg thrice
a day) n = 31, DRUG 3 (cap Velgut (5 billion CFUs of Bifidobacterium breve, Bifidobacterium longum, Bi-
fidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lacto-
Sharma 2014 
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bacillus rhamnosus, Streptococcus thermophilus, Saccharomyces boulardii)1 capsule twice a day) n = 32,
and DRUG 4 (placebo twice a day) n = 30.
Outcomes 1. Death.
2. Recovery from MHE.
3. Overt HE.
4. CFF.
Notes Contacted Dr K Sharma on 14 March 2015, received no response.
Funding source: "Source of Support: Nil, Conflict of Interest: None declared". This study declared the
funding source and was deemed to be independently funded.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk "the block randomization method was utilized for random allocation of
drugs."
Allocation concealment Low risk "The sequence remained concealed from the investigator and the generator of
the random blocks did not participate in screening, enrolment, or drug deliv-
ery."
Blinding 
Participants
High risk The study was not blinded.
Blinding 
Personnel
High risk The study was not blinded.
Blinding 
Outcome assessors
High risk The study was not blinded.
Incomplete outcome data 
All outcomes
Unclear risk A total of 20 participants could not be followed up to the end of the study: 10
were lost to follow-up, 6 went into overt HE, and 4 expired. Of the total 10 par-
ticipants lost to follow-up, the most were in the LOLA group (4 cases) followed
by the placebo group (3 cases). The largest number of deteriorations in clinical
state, i.e. development of overt HE, occurred in the placebo group (3 cases). Of
the total 4 deaths, 2 were in the placebo group and 1 each was in the rifaximin
and Velgut groups. There were no deaths in the LOLA group.
Selective outcome report-
ing
Unclear risk "Maximal number of deteriorations in clinical state, that is, development of
overt HE among patients occurred in the placebo (3 cases) group."
Overt HE development was not well reported.
Funding source Low risk "Source of Support: Nil, Conflict of Interest: None declared."
Sharma 2014  (Continued)
 
 
Methods Design: randomised parallel trial + non-randomised cohort study
Trial duration: 10 weeks
Treatment duration: 2 weeks
Shavakhi 2014 
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Participants Setting: The study was conducted on adults with MHE referred consecutively to the gastroenterology
clinic of a university hospital in Isfahan city (Iran) between June and October 2012.
Country: Iran
Age range (years): range not given, mean age (SD) 38.4 (9.6) years
Total numbers randomised: total (Gp-LPr/Gp-L): 46 (23/23)
Sex (M/F): 48/12
Language: unspecified
Stage/severity of hepatic encephalopathy: minimal hepatic encephalopathy; Child-Pugh score A/B/C:
8/37/14 (data missing for 1 participant)
Cause of hepatic encephalopathy: viral/autoimmune/other: 44/11/5
Inclusions: The study was conducted on adults with MHE referred consecutively to the gastroenterolo-
gy clinic of a university hospital in Isfahan city (Iran) between June and October 2012. Cirrhosis was di-
agnosed histologically (unless biopsy was contraindicated) and on clinical and radiological grounds.
Diagnosis of MHE was based on the Conn’s modification of the Parsons-Smith classification (grade 1
and above).
Exclusions: People with overt HE, known brain lesions, active gastrointestinal bleeding, active ongo-
ing infection, renal impairment (serum creatinine > 2 mg/dL), electrolyte abnormalities (serum sodium
< 130 or > 150 meq/dL, serum potassium < 3.0 or > 5.5 meq/dL), and those who had received HE treat-
ments such as lactulose and antibiotics or consumed benzodiazepines, narcotics, opioids, or alcohol in
the preceding 8 weeks were not included in the trial.
Interventions Participants were randomised into 2 groups: lactulose + probiotic (Gp-LPr) and lactulose + placebo (Gp-
L). Another non-randomised group of participants who received probiotic alone (Gp-Pr) were included
separately for further comparisons; this group received neither placebo nor lactulose.
All participants received routine treatment for cirrhosis, including diuretics, β-blockers, endoscopic
treatment, and a salt-restricted diet but not protein-restricted diet in those with ascites. For Gp-LPr and
Gp-L, lactulose syrup was administered as 30 to 60 mL/day in divided doses for a stool frequency of 2
to 3 soT defecations per day. For Gp-LPr and Gp-Pr, a multistrain probiotics compound, Balance (Pro-
texin Co., Somerset, UK), was administered twice daily after meal. Balance capsules contain 7 bacteria
species including Lactobacillus strains (L casei, L rhamnosus, L acidophilus, and L bulgaricus), Bifidobac-
terium strains (B breve and B longum), and Streptococcus thermophilus. Total viable count is 1 × 108 CFU
per capsule. Other ingredients are fructo-oligosaccharides as prebiotic, magnesium stearate, and hy-
droxypropyl methyl cellulose. These interventions were continued for 14 consecutive days, and compli-
ance was assessed with pill and bottle count.
Outcomes Primary endpoint was improvement in MHE status, which was assessed by applying the PHES at base-
line, 14 days after start of the intervention (14th day), and then at 8 weeks' follow-up (10th week). The
PHES is a set of neuropsychological tests including the Line-Tracing Test, Digit Symbol Test, Serial Dot-
ting Test, and Number Connection Test. These tests are used in the diagnosis and grading of MHE and
examine visual perception, visuospatial orientation, visual construction, motor speed and accuracy,
concentration, attention, and memory. Participants could achieve between +6 and −18 points.
Secondary outcomes were development of overt HE, admission to hospital for any other complication
of cirrhosis, or death.
Notes The study was also registered at Iranian Registry of Clinical Trials (IRCT201211012417N9).
Contacted Dr A Shavakhi on 14 March 2015, received no response.
Funding source: "Source of Support: Isfahan University of Medical Sciences, Potential competing in-
terests: None declared". This study declared the funding source and was deemed to be independently
funded.
Shavakhi 2014  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk "Using a table of random numbers generated by random allocation software,
patients were randomized into two groups".
Allocation concealment Unclear risk Unclear from study
Blinding 
Participants
High risk "Because we could not provide an appropriate placebo for lactulose, our study
was not completely randomized and double blinded, which could affect our
results."
Blinding 
Personnel
High risk "Because we could not provide an appropriate placebo for lactulose, our study
was not completely randomized and double blinded, which could affect our
results."
Blinding 
Outcome assessors
Unclear risk Although the trial was not blinded, the objective nature of the tests for MHE
would likely limit the effect of bias on MHE recovery outcomes.
Incomplete outcome data 
All outcomes
Low risk "After randomization, two patients from the Gp-L, four patients from the Gp-
LPr, and three patients from the Gp-Pr declined to receive intervention. Finally,
60 adult patients with cirrhosis (80% male, mean age 38.4 ± 9.6 years) started
the trial and completed the intervention."
"During the follow-up period, one patient from each of the Gp-LPr and Gp-L
was lost to follow-up."
Selective outcome report-
ing
Unclear risk The outcomes to be measured were not clearly specified in trial as registered
at Iranian Registry of Clinical Trials (trial number IRCT201211012417N9).
Funding source Low risk "Source of Support: Isfahan University of Medical Sciences, Potential compet-
ing interests: None declared."
Shavakhi 2014  (Continued)
 
 
Methods Design: a randomised parallel trial
Trial duration: 12 weeks
Treatment duration: 12 weeks
Participants Setting: unspecified
Country: Greece
Age range (years): range unspecified, mean (SD): 59 (10)
Total numbers randomised: 72
Sex (M/F): 62/10
Language: unspecified
Stage/severity of hepatic encephalopathy: minimal hepatic encephalopathy; "Mean (SD) Child-Pugh
score: 6.4 (1.6), 46% Child-Pugh A, mean (SD) MELD score: 11.9 (3.6)"
Cause of hepatic encephalopathy: 58% alcoholic cirrhosis
Vlachogiannakos 2014 
Probiotics for people with hepatic encephalopathy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
62
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Inclusions: "In a period of 18 months, we screened 142 consecutive patients without overt HE for MHE
using both, psychometric (number connection test, NCT) and neurophysiological (brainstem auditory
evoked potentials, BAEP) modalities."
Exclusions: unclear from abstract
Interventions 72 participants were equally randomised into Lactobacillus plantarum 299v at a dose of 1010 units per
sachet (Lp299v) or identical placebo, given twice a day for a period of 12 weeks.
Outcomes 1. Development of overt HE.
2. Adherence to treatment.
3. MHE reversal.
4. Psychometric test score (NCT, BAEP).
5. Serum fasting ammonia.
Notes Contaced Dr J Vlachogiannakos on 22 December 2014, received no response.
Funding source: abstract only, unable to assess
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Unclear risk Abstract only, unable to assess
Allocation concealment Unclear risk Abstract only, unable to assess
Blinding 
Participants
Low risk "identical placebo" used
Blinding 
Personnel
Unclear risk Abstract only, unable to assess
Blinding 
Outcome assessors
Unclear risk Abstract only, unable to assess
Incomplete outcome data 
All outcomes
Unclear risk Abstract only, unable to assess
Selective outcome report-
ing
Unclear risk Abstract only, unable to assess
Funding source Unclear risk Abstract only, unable to assess
Vlachogiannakos 2014  (Continued)
 
 
Methods Design: randomised controlled trial
Trial duration: 1 month
Treatment duration: 1 month
Participants Setting: hospital gastroenterology clinic
Country: China
Zhao 2013 
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Age range (years): range unspecified, mean (SD): control group 41.15 (11.85), lactulose group 43.85
(11.10), probiotic group 44.25 (11.85)
Total numbers randomised: 120
Sex (M/F): 92/28
Language: Chinese language/s, with psychometric testing language adjusted to suit population
Stage/severity of hepatic encephalopathy: minimal hepatic encephalopathy; CTP A/B/C: 50/39/31
Cause of hepatic encephalopathy: chronic hepatitis B
Inclusions:
• Compliance with chronic hepatitis B prevention and treatment guidelines.• Diagnosed with MHE based on psychometric testing.
Exclusions:
• Clinical symptoms of HE.• Clinical symptoms of HE in last 6 weeks.• History of upper GI bleeding in the last 6 weeks.• Active infection.• Renal impairment and creatinine greater than 133 µM/L.• Electrolyte abnormality (Na+ < 130 mM/L or > 150 mM/L; K+ < 3 mM/L or > 5.5 mM/L).• People with alcoholic cirrhosis.• Recently taking antibiotics, probiotics, or aspartate/ornithine.• Took psychotropic drugs in the last 6 weeks.• TIPS shunt.• Surgery.• Liver tumours.• Serious systemic disease such as heart failure, pulmonary disease, neurological and psychiatric ill-
ness.• Visual impairment.• Impairment on intelligence tests.
Interventions Standard treatment of liver cirrhosis (control) compared to both lactulose (twice daily, 30 to 60 mL with
soT stools 2 to 3 times daily) and probiotic (110 million CFU twice daily for 1 month) groups.
Outcomes 1. All-cause mortality.
2. MHE improvement.
3. Arterial ammonia level.
4. Adverse effects.
5. Change of/withdrawal from treatment.
Notes We found no contact details.
Funding source: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk Randomised table used.
Allocation concealment Unclear risk Unclear from study
Zhao 2013  (Continued)
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Blinding 
Participants
Unclear risk Unclear from study
Blinding 
Personnel
Unclear risk Unclear from study
Blinding 
Outcome assessors
Unclear risk Unclear from study
Incomplete outcome data 
All outcomes
Unclear risk Unclear from study
Selective outcome report-
ing
Unclear risk Unclear from study
Funding source Unclear risk Unclear from study
Zhao 2013  (Continued)
 
 
Methods Design: unclear from abstract
Trial duration: unclear from abstract
Treatment duration: unclear from abstract
Participants Setting: unclear from abstract
Country: China
Age range (years): unclear from abstract
Total numbers randomised: 30
Sex (M/F): unclear from abstract
Language: unclear from abstract
Stage/severity of hepatic encephalopathy: hepatic encephalopathy (excluding clinical IV stage)
Cause of hepatic encephalopathy: unclear from abstract
Inclusions: unclear from abstract
Exclusions: unclear from abstract
Interventions Treatment group: routine liver protection against hepatic coma therapy, oral or nasal feeding of live
Bacillus cereus capsules
Control group: conventional liver protection against hepatic coma therapy, oral or nasal feeding of lac-
tulose
Outcomes 1. Resolution of hepatic encephalopathy.
2. Blood ammonia levels.
Notes We found no contact details.
Funding source: abstract only, unable to assess
Zhitai 2013 
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Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Unclear risk Abstract only, unable to assess
Allocation concealment Unclear risk Abstract only, unable to assess
Blinding 
Participants
Unclear risk Abstract only, unable to assess
Blinding 
Personnel
Unclear risk Abstract only, unable to assess
Blinding 
Outcome assessors
Unclear risk Abstract only, unable to assess
Incomplete outcome data 
All outcomes
Unclear risk Abstract only, unable to assess
Selective outcome report-
ing
Unclear risk Abstract only, unable to assess
Funding source Unclear risk Abstract only, unable to assess
Zhitai 2013  (Continued)
 
 
Methods Design: randomised parallel trial
Trial duration: 1 month
Treatment duration: 1 month
Participants Setting: outpatient clinic and inpatient wards
Country: Egypt
Age range (years): range unclear, group A/B /C mean (SD): 48.8 (8.2)/50.3 (7.8)/51.2 (7.5)
Total numbers randomised: 90
Sex (M/F): 55/20 (excluding attrition)
Language: unspecified
Stage/severity of hepatic encephalopathy: minimal hepatic encephalopathy screened by NCT-A, DST,
and SDT; Child A/B/C: 8/41/26
Cause of hepatic encephalopathy: unspecified
Inclusions: All cirrhotic patients attending the Tropical Medicine and Infectious Disease outpatient clin-
ic and inpatient wards from March 2010 to January 2012 were encouraged to join this prospective ran-
domised trial.
Exclusions: The exclusion criteria were the presence of overt HE, alcohol intake, gastrointestinal haem-
orrhage or spontaneous bacterial peritonitis during the past 6 weeks, previous shunt surgery and
associated heart, respiratory, or renal failure as well as history of any neurologic or metabolic en-
cephalopathies. People on psychoactive drugs such as antidepressants or sedatives were excluded.
Ziada 2013 
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Interventions Group A received lactulose (30 to 60 mL/day); group B received a probiotic (1 capsule containing 106
Lactobacillus acidophilus 3 times/day); and group C was the control.
Outcomes 1. Psychometric tests (normalisation, persistence of abnormality in 1 psychometric test, no improve-
ment).
2. Gut microecology study.
3. Ammonia level.
4. Brain metabolites using MRS.
Notes Contacted Dr DH Ziada on 14 March 2015, received no response.
Funding source: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Unclear risk "Patients were allocated by simple randomisation to three parallel equal
groups of 30 patients each."
Allocation concealment Unclear risk Unclear from study
Blinding 
Participants
High risk "This study was designed as overtime open-label randomised controlled tri-
al testing the role of a probiotic in comparison with lactulose or no therapy in
MHE patients."
Blinding 
Personnel
High risk "This study was designed as overtime open-label randomised controlled tri-
al testing the role of a probiotic in comparison with lactulose or no therapy in
MHE patients."
Blinding 
Outcome assessors
Low risk Although the trial was not blinded, the objective nature of the tests for MHE
would likely limit the effect of bias on MHE recovery outcomes.
Incomplete outcome data 
All outcomes
Low risk Group A: 30 allocated to lactulose, 30 received lactulose, 2 lost to follow-up, 2
discontinued therapy, 2 overt encephalopathy, 24 participants analysed.
Group B: 30 allocated to probiotics, 30 received probiotics, 2 lost to follow-up,
1 discontinued therapy, 1 overt encephalopathy, 26 participants analysed.
Group C: 30 allocated, 0 lost to follow-up, 5 overt encephalopathy, 25
analysed.
Selective outcome report-
ing
Unclear risk Unable to assess
Funding source Unclear risk "The authors declared that there is no conflict of interest".
Ziada 2013  (Continued)
ALT = alanine aminotransferase; BAEP = brainstem auditory evoked potentials; CFF = critical flicker frequency; CFU = colony forming unit;
CNS = central nervous system; CT = computed tomography; CTP = Child-Turcotte-Pugh; DST = digit symbol test; FCT = figure connection
test; GI = gastrointestinal; HBV = hepatitis B virus; HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus; HE = hepatic encephalopathy;
HRQOL = health-related quality of life; IL-6 = interleukin 6; LOLA = L-ornithine-L-aspartate; MCS = Mental Component summary; MELD =
Model for End-Stage Liver Disease; MHE = minimal hepatic encephalopathy; MRS = Magnetic resonance spectroscopy; NASH = non-alcoholic
steatohepatitis;
NCT = Number Connection Test; NIH = National Institutes of Health; NPT = neuropsychological testing; OCTT = orocaecal transit time;
OHE = overt hepatic encephalopathy; PHES = psychometric hepatic encephalopathy score; QOL= quality of life; SD = standard deviation;
SDT = serial dotting test; SF-36 = 36-Item Short Form Health Survey; SIBO = small intestinal bacterial overgrowth; TIPS = transjugular
intrahepatic portosystemic shunt; TNF alpha = tumour necrosis factor-alpha; USG = ultrasonography
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adams 2006 No hepatic encephalopathy patients involved
Agrawal 2012 Not a randomised trial
Agrawal 2012a Hepatic encephalopathy not used as participant selection criteria
Al 2009 Not a randomised trial
Albillos 2002 No hepatic encephalopathy patients involved
Alisi 2014 No hepatic encephalopathy patients involved
Aller 2011 No hepatic encephalopathy patients involved
Almeida 2006 Not a randomised trial
Arya 2010 Not a randomised trial
Bai 2013 Not a randomised trial
Bajaj 2008a Not a randomised trial
Bajaj 2008b Not a randomised trial
Bajaj 2014 Not a randomised trial
Barclay 2011 Not a randomised trial
Barreto-Zuniga 2001 No hepatic encephalopathy patients involved
Bass 2007 Not a randomised trial
Bengmark 2009a Not a randomised trial
Bengmark 2011 Not a randomised trial
Bengmark 2013 Not a randomised trial
Bismuth 2011 Not a randomised trial
Boca 2004 Not a randomised trial
Bongaerts 2005 Not a randomised trial
Cabre 2005 Not a randomised trial
Cash 2010 Not a randomised trial
Chadalavada 2010 Not a randomised trial
Chauhan 2012 Not a randomised trial
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Study Reason for exclusion
Cheung 2012 Not a randomised trial
Chikhacheva 2014 Not a randomised trial
Ciorba 2012 Not a randomised trial
Colle 1989 Hepatic encephalopathy not confirmed
Conn 1970 Not a randomised trial
Crittenden 2013 Not a randomised trial
Dai 2014 No probiotic used
Dasarathy 2003 No probiotic used
Dbouk 2006 Not a randomised trial
De Micco 2012 Not a randomised trial
Demeter 2006 Not a randomised trial
Dhiman 2004 Not a randomised trial
Dhiman 2007 Not a randomised trial
Dhiman 2009 Not a randomised trial
Dhiman 2010 Not a randomised trial
Dhiman 2012 Hepatic encephalopathy not used as participant selection criteria
Dhiman 2013 Not a randomised trial
Dhiman 2014 Hepatic encephalopathy not used as participant selection criteria
Dhiman 2015 Not a randomised trial
Ding 2014 Not a randomised trial
Ding 2014a Not a randomised trial
Doron 2005 Not a randomised trial
Druart 2014 Not a randomised trial
Dylag 2014 Not a randomised trial
EASL 2012 Not a randomised trial
Eguchi 2011 Not probiotic
El-Nezami 2006 No hepatic encephalopathy patients involved
Eslamparast 2014 No hepatic encephalopathy patients involved
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Study Reason for exclusion
Fan 2009 No hepatic encephalopathy patients involved
Fan 2013 Not a randomised trial
Fehervari 2012 Not a randomised trial
Ferenci 2001 Not a randomised trial
Ferenci 2007 Not a randomised trial
Feret 2010 Not probiotic
Ferreira 2010 Not a randomised trial
Festi 2014 Not a randomised trial
Finney 2007 No probiotics used
Floch 2015 Not a randomised trial
Fontana 2013 Not a randomised trial
Fooladi 2013 Not a randomised trial
Foster 2010 Not a randomised trial
Fujita 2008 No hepatic encephalopathy patients involved
Fuster 2007 Not a randomised trial
Galhenage 2006 Not a randomised trial
Ganguli 2013 No hepatic encephalopathy patients involved
Garcia 2012 Not a randomised trial
Garcovich 2012 Not a randomised trial
Gareau 2014 Not a randomised trial
Gluud 2013 Not a randomised trial
Gomez-Hurtado 2014 Not a randomised trial
Grat 2014 Not a randomised trial
Gratz 2010 Not a randomised trial
Greco 2007 Groups non-comparable
Gu 2014 No hepatic encephalopathy patients involved
Guarner 2009 Not a randomised trial
Guarner 2012 Not a randomised trial
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Study Reason for exclusion
Guerrero 2008 Not a randomised trial
Gupta 2010 No hepatic encephalopathy patients involved
Gupta 2010a No hepatic encephalopathy patients involved
Gupta 2013 No hepatic encephalopathy patients involved
Hellinger 2002 No probiotic used
Higashikawa 2010 No hepatic encephalopathy patients involved
Holte 2012 Not a randomised trial
Hotten 2003 No hepatic encephalopathy patients involved
Hutt 2011 Not a randomised trial
Ianiro 2014 Not a randomised trial
Iannitti 2010 Not a randomised trial
Imler 1971 Not a randomised trial
Ivanovic 2015 Not a randomised trial
Janczyk 2012 Not a randomised trial
Jayakumar 2012 No hepatic encephalopathy patients involved
Jayakumar 2013 No hepatic encephalopathy patients involved
Jeejeebhoy 2004 Not a randomised trial
Jiang 2008 No probiotics used
Jones 2013 No hepatic encephalopathy patients involved
Jonkers 2007 Not a randomised trial
Jover-Cobos 2014 Not a randomised trial
Jun 2013 No hepatic encephalopathy patients involved
Jurado 2012 Not a randomised trial
Kachaamy 2011 Not a randomised trial
Kadayifci 2007 Not a randomised trial
Karczewski 2010 No hepatic encephalopathy patients involved
Keeffe 2007 Not a randomised trial
Khungar 2012 Not a randomised trial
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Study Reason for exclusion
Kirpich 2008 No hepatic encephalopathy patients involved
Kitagawa 2015 Not a randomised trial
Koga 2013 No hepatic encephalopathy patients involved
Kremer 1974 Not a randomised trial
Kumashiro 2008 Not a randomised trial
Kwak 2014 No hepatic encephalopathy patients involved
Lata 2006 No hepatic encephalopathy patients involved
Lata 2007 No hepatic encephalopathy patients involved
Lata 2007a No hepatic encephalopathy patients involved
Lata 2009 No hepatic encephalopathy patients involved
Lata 2011 Not a randomised trial
Leber 2012 Not a randomised trial
Liboredo 2015 Not a randomised trial
Lien 2015 No hepatic encephalopathy patients involved
Lighthouse 2004 No hepatic encephalopathy patients involved
Liu 2006 Not available
Liu 2009 Not available
Liu 2010 Not a randomised trial
Liu 2012 Not a randomised trial
Llorente 2015 Not a randomised trial
Loguercio 2002 No hepatic encephalopathy patients involved
Loguercio 2005 No hepatic encephalopathy patients involved
Louvet 2015 Not a randomised trial
Lu 2011 Not a randomised trial
Luna 2010 Hepatic encephalopathy not used as patient selection criteria
Lunia 2012 Hepatic encephalopathy not used as patient selection criteria
Lunia 2014a Hepatic encephalopathy not used as patient selection criteria
Luo 2011 Not a randomised trial
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Study Reason for exclusion
Ma 2013 Not a randomised trial
Machado 2012 Not a randomised trial
Madsen 2008 No hepatic encephalopathy patients involved
Malaguarnera 2007 Not a probiotic alone
Malaguarnera 2012 No hepatic encephalopathy patients involved
Marteau 2001 Not a randomised trial
Marteau 2002 Not a randomised trial
Marteu 2001 Not a randomised trial
Michelfelder 2010 Not a randomised trial
Minemura 2015 Not a randomised trial
Mishra 2012 Not a randomised trial
Mohammad 2012 Not a randomised trial
Montagnese 2012 Not a randomised trial
Montgomery 2011 Not a randomised trial
Montrose 2005 Not a randomised trial
Moreno-Luna 2011 Not a randomised trial
Morgan 2007 Not a randomised trial
Mullen 2007 Not a randomised trial
Nabavi 2014 No hepatic encephalopathy patients involved
Nazir 2010 Prophylaxis, not treatment
NCT01135628 Not a randomised trial
Olveira 2007 Not a randomised trial
Oshea 2010 Not a randomised trial
Pande 2009 No hepatic encephalopathy patients involved
Pande 2012 No hepatic encephalopathy patients involved
Paolella 2014 Not a randomised trial
Park 2007 Not a randomised trial
Patel 2015 Not a randomised trial
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Study Reason for exclusion
Pawar 2012 Hepatic encephalopathy not used as participant selection criteria
Phongsamran 2010 Not a randomised trial
Plaza-Diaz 2014 No hepatic encephalopathy patients involved
Poh 2012 Not a randomised trial
Poustchi 2013 No hepatic encephalopathy patients involved
Prakash 2013 Not a randomised trial
Quigley 2006 Not a randomised trial
Quigley 2013 Not a randomised trial
Quigley 2014 Not a randomised trial
Quigley 2014a Not a randomised trial
Rahimi 2012 Not a randomised trial
Rahimi 2013 Not a randomised trial
Rayes 2001 No hepatic encephalopathy patients involved
Rayes 2002 No hepatic encephalopathy patients involved
Rayes 2005 No hepatic encephalopathy patients involved
Rayes 2012 No hepatic encephalopathy patients involved
Read 1966 Not a randomised trial
Reddy 2013 Not a randomised trial
Rifatbegovic 2010 No hepatic encephalopathy patients involved
Riggio 2009 Not a randomised trial
Rincon 2014 Not a randomised trial
Riordan 2007 No hepatic encephalopathy patients involved
Riordan 2010 No probiotic used
Rivkin 2011 Not a randomised trial
Romero-Gomez 2010 Not a randomised trial
Sanchez 2015 No hepatic encephalopathy patients involved
Scevola 1989 No probiotics used
Schiano 2010 Not a randomised trial
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Study Reason for exclusion
Schuster-WolJ-Bühring 2010a Not a randomised trial
Schuster-WolJ-Bühring 2010b Not a randomised trial
Segura-Ortega 2010 No hepatic encephalopathy patients involved
Shang 2013 No hepatic encephalopathy patients involved
Sharma 2010 Not a randomised trial
Sharma 2012 No probiotic used
Sharma 2013 Not a randomised trial
Sharma 2014a Hepatic encephalopathy not used as participant selection criteria
Sharma 2014b Not a randomised trial
Sharma 2015 Not a randomised trial
Shawcross 2005 Not a randomised trial
Shen 2013 Not available
Shen 2014 Not available
Sheth 2008 Not a randomised trial
Shu 2008 Not available
Shukla 2009 Not a randomised trial
Shukla 2010 Not a randomised trial
Shukla 2010a Not a randomised trial
Shukla 2011 Not a randomised trial
Solga 2003 Not a randomised trial
Soriano 2013 Not a randomised trial
Soriano 2013a Not a randomised trial
Stadlbauer 2008 No hepatic encephalopathy patients involved
Stewart 2007 Not a randomised trial
Strasser 2011 Not a randomised trial
Suk 2012 No hepatic encephalopathy patients involved
Sundaram 2009 Not a randomised trial
Tang 2011 Not a randomised trial
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Tapper 2015 Not a randomised trial
Tarantino 2015 Not a randomised trial
Tarao 1995 No probiotics used
Tojo 2014 Not a randomised trial
Toris 2011 Not a randomised trial
Tsochatzis 2012 Not a randomised trial
Tsochatzis 2014 Not a randomised trial
Upadhyay 2012 Not a randomised trial
Usami 2011 No hepatic encephalopathy patients involved
Valentini 2015 No hepatic encephalopathy patients involved
Videhult 2015 No hepatic encephalopathy patients involved
Vilstrup 2014 Not a randomised trial
Vilstrup 2014a Not a randomised trial
Vyas 2012 Not a randomised trial
Waghray 2014 Not a randomised trial
Waghray 2015 Not a randomised trial
Wang 2012 Not available
Wang 2015 Not available
Welliver 2012 Not a randomised trial
Wong 2013a No hepatic encephalopathy patients involved
Woo 2012 Not a randomised trial
Wright 2007 Not a randomised trial
Wu 2008 Not a randomised trial
Xu 2012 Not a randomised trial
Xu 2014 Not a randomised trial
Xu 2014a Not a randomised trial
Yakabe 2009 No hepatic encephalopathy patients involved
Yao 2014 Not a randomised trial
Probiotics for people with hepatic encephalopathy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
76
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study Reason for exclusion
Yasutake 2012 Not a randomised trial
Zafirova 2010 Not a randomised trial
Zamberlin 2012 Not a randomised trial
Zhang 2014 Not a randomised trial
Zhao 2004 No hepatic encephalopathy patients involved
Zucker 2014 Not a randomised trial
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Design: randomised controlled trial
Trial duration: 2 months
Treatment duration: 2 months
Participants Country: Australia
Age range (years):
Total numbers randomised: 80 target sample size
Inclusions: Child's B or C cirrhosis on lactulose aged between 18 and 70 years who are abstinent
from alcohol and illegal drugs for at least 6 months. If on methadone, must be dose stable for > 6
months.
Exclusions:
• Pregnancy.• < 18 years.• > 70 years.• Current alcohol use.• Current intravenous drug use.• Sepsis.• Grade 4 encephalopathy.
Interventions 1. Synbiotics + branched-chain amino acids (BCAAs).
2. BCAAs + placebo for synbiotics.
3. Placebo for BCAAs + placebo for synbiotics.
Synbiotic 2000 Forte is packaged in 10-gram single-dose sachets containing the following: Natur-
al and digestible fibres: * 2.5 g oat bran; * 2.5 g pectin; * 2.5 g resistant starch; * 2.5 g inulin. Probi-
otic bacteria: * Lactobacillus paracasei ssp paracasei 10 x 1011; * Lactobacillus plantarum 10 x 1011;
* Leuconostoc mesenteroides 10 x 1011; * Pediococcus pentosaceus 10 x 1011 (Medipharm). Dose is
1 sachet/day mixed with juice, jam, or honey according to participant's tolerance. Duration of sup-
plementation is 56 days.
Branched-chain amino acid preparation is HepatAmine (Nutricia), which is a mixture of branched-
chain amino acids + sugars. Dose is 1 sachet at night mixed with 200 mL lemonade or fruit juice. Du-
ration of supplementation is 56 days.
ACTRN12610001021066 
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Placebo for synbiotics is 10 g crystalline starch packaged similarly to Synbiotic 2000 Forte. Dose is
1 sachet/day mixed with juice, jam, or honey according to participant's tolerance. Duration of sup-
plementation is 56 days. Placebo for BCAAs is 29 g glucose + 15 g Vitafresh. Dose is 1 sachet at night
mixed with 200 mL lemonade or fruit juice. Duration of supplementation is 56 days.
Outcomes Primary outcome:
1. Effects of supplementation with synbiotics and/or BCAAs on levels of hepatic encephalopathy
(Trail Making Tests A and B and the Inhibitory Control Test).
Secondary outcomes:
1. Effects of synbiotics or BCAAs or both on quality of life outcomes measured by liver disease short
form quality of life (SFLDQOL) questionnaire and depression and anxiety score (DASS).
2. Effects of supplementation with synbiotics or BCAAs or both on frequency of hospitalisation.
3. Effects of supplementation with synbiotics or BCAAs or both on severity of the participant's chron-
ic liver disease using the Child-Pugh Score and Model for End-Stage Liver Disease (MELD).
4. Effects of supplementation with synbiotics or BCAAs or both on body composition and hand grip
strength. (Body composition is assessed by anthropometry, measurements of midarm circumfer-
ence and triceps skinfold and calculated midarm muscle circumference. Hand grip strength is
measured using a dynamometer.)
5. Effects of supplementation with synbiotics or BCAAs or both on appetite and oral intake. (Appetite
is a subjective assessment by the participant using a visual analogue scale. Oral intake is assessed
using a 3-day food history recorded by the participant at each time point).
Notes Data obtained from trial registry www.anzctr.org.au/, trial ID: ACTRN12610001021066.
ACTRN12610001021066  (Continued)
 
 
Methods Design: randomised controlled trial
Trial duration: 14 days
Treatment duration: 14 days
Participants Country: Iran
Age range: between 18 to 65 years
Total number randomised: target sample size 40
Inclusion criteria:
• Age between 18 to 65 years.• Diagnosis of hepatic encephalopathy.• Filling consent form.
Exclusion criteria:
• Refusal to fill consent form.• Active gastrointestinal bleeding.• Alcohol usage.• Active infection.• Lactolos or antibiotic therapy within the previous 2 weeks.• Space-occupying lesion in central nervous system.
Interventions Intervention 1: probiotic capsule (Protexin).
IRCT201211012417N9 
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Intervention 2: placebo capsule.
Outcomes Consiousness level. (Time point: beginning and 14 days postintervention. Method of measurement:
questionnaire.)
Notes Data obtained from apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201211012417N9.
IRCT201211012417N9  (Continued)
 
 
Methods Design: randomised controlled trial
Trial duration: 15 weeks
Treatment duration: 15 weeks
Participants Country: Italy
Age range (years): 4 to 20
Total numbers randomised: target sample size 50
Inclusion criteria:
• Extra-hepatic portal vein thrombosis.• Age between 4 and 20 years.• Knowledge of Italian language.• Absence of perceptive or communicative deficit.• Absence of psychiatric disease or mental retardation.
Exclusion criteria:
• Medical contraindications for required evaluations.• Infective pathologies.• Parenchymal hepatic pathologies.
Interventions Dietary supplement: probiotic VSL#3
Outcomes Primary outcome
1. Neuropsychological and electrophysiological aspects [Time Frame: after 15 weeks of probiotic or
placebo treatment].
Secondary outcomes
1. Abdomen scan with colour Doppler technique [Time Frame: after 15 weeks of probiotic or placebo
treatment].
2. Biochemical blood test [Time Frame: after 15 weeks of probiotic or placebo treatment].
3. Bowel frequency and characteristics [Time Frame: after 15 weeks of probiotic or placebo treat-
ment].
4. Dietary anamnesis (last 3 days) [Time Frame: after 15 weeks of probiotic or placebo treatment].
5. Neurological evaluation [Time Frame: after 15 weeks of probiotic or placebo treatment].
6. Urine and faeces analysis [Time Frame: after 15 weeks of probiotic or placebo treatment].
Notes Data obtained from apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01798329.
NCT01798329 
 
Probiotics for people with hepatic encephalopathy (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
79
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Probiotic versus placebo or no intervention
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 All-cause mortality 7 404 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.23, 1.44]
1.1 2 weeks 1 46 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 1 month 1 80 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 7.95]
1.3 2 months 3 117 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.11, 4.66]
1.4 3 months 2 161 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.19, 1.74]
2 No recovery (incomplete resolu-
tion of clinical symptoms)
10 574 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.56, 0.79]
2.1 1 month 4 228 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.58, 0.96]
2.2 2 months 3 117 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.38, 1.10]
2.3 3 months 3 229 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.43, 0.78]
3 Adverse events 11   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Overt hepatic encephalopathy 10 585 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.16, 0.51]
3.2 Infection 1 37 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Hospitalisation 3 163 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.11, 4.00]
3.4 Intolerance leading to discontin-
uation
1 37 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 Change of/or withdrawal from
treatment
9 551 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.46, 1.07]
4 Quality of life 3   Mean Difference (IV, Random, 95%
CI)
Subtotals only
4.1 SF-36 Physical 1 20 Mean Difference (IV, Random, 95%
CI)
0.0 [-5.47, 5.47]
4.2 SF-36 Mental 1 20 Mean Difference (IV, Random, 95%
CI)
-4.0 [-9.82, 1.82]
4.3 Change in Total SIP Score 2 95 Mean Difference (IV, Random, 95%
CI)
-3.66 [-7.75, 0.44]
4.4 Change in SIP Psychological
Score
2 95 Mean Difference (IV, Random, 95%
CI)
-3.54 [-4.95, -2.12]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4.5 Change in SIP Physical Score 2 95 Mean Difference (IV, Random, 95%
CI)
-2.94 [-4.44, -1.44]
5 Plasma ammonia concentration
(final and change scores) (μmol/L)
10 705 Mean Difference (IV, Random, 95%
CI)
-8.29 [-13.17, -3.41]
5.1 1 month 5 357 Mean Difference (IV, Random, 95%
CI)
-5.55 [-10.67, -0.42]
5.2 2 months 4 211 Mean Difference (IV, Random, 95%
CI)
-5.11 [-14.56, 4.34]
5.3 3 months 1 73 Mean Difference (IV, Random, 95%
CI)
-6.79 [-10.39, -3.19]
5.4 6 months 1 64 Mean Difference (IV, Random, 95%
CI)
-31.08 [-40.50, -21.66]
 
 
Analysis 1.1.   Comparison 1 Probiotic versus placebo or no intervention, Outcome 1 All-cause mortality.
Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 2 weeks  
Shavakhi 2014 0/23 0/23   Not estimable
Subtotal (95% CI) 23 23 Not estimable
Total events: 0 (Probiotic), 0 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.1.2 1 month  
Zhao 2013 0/40 1/40 8.33% 0.33[0.01,7.95]
Subtotal (95% CI) 40 40 8.33% 0.33[0.01,7.95]
Total events: 0 (Probiotic), 1 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.68(P=0.5)  
   
1.1.3 2 months  
Bajaj 2014a 0/14 0/16   Not estimable
Bajaj 2008 1/17 0/8 8.73% 1.5[0.07,33.26]
Sharma 2014 1/32 2/30 15.2% 0.47[0.04,4.91]
Subtotal (95% CI) 63 54 23.92% 0.72[0.11,4.66]
Total events: 2 (Probiotic), 2 (No intervention)  
Heterogeneity: Tau2=0; Chi2=0.34, df=1(P=0.56); I2=0%  
Test for overall effect: Z=0.35(P=0.73)  
   
1.1.4 3 months  
Mittal 2009 0/40 1/40 8.33% 0.33[0.01,7.95]
Lunia 2014 4/42 6/39 59.41% 0.62[0.19,2.03]
Favours probiotic 2000.005 100.1 1 Favours control
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Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 82 79 67.74% 0.57[0.19,1.74]
Total events: 4 (Probiotic), 7 (No intervention)  
Heterogeneity: Tau2=0; Chi2=0.13, df=1(P=0.72); I2=0%  
Test for overall effect: Z=0.98(P=0.33)  
   
Total (95% CI) 208 196 100% 0.58[0.23,1.44]
Total events: 6 (Probiotic), 10 (No intervention)  
Heterogeneity: Tau2=0; Chi2=0.64, df=4(P=0.96); I2=0%  
Test for overall effect: Z=1.17(P=0.24)  
Test for subgroup differences: Chi2=0.17, df=1 (P=0.92), I2=0%  
Favours probiotic 2000.005 100.1 1 Favours control
 
 
Analysis 1.2.   Comparison 1 Probiotic versus placebo or no intervention,
Outcome 2 No recovery (incomplete resolution of clinical symptoms).
Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 1 month  
Liu 2004 10/20 10/20 6% 1[0.54,1.86]
Sharma 2008 13/30 14/31 6.86% 0.96[0.55,1.69]
Ziada 2013 13/27 27/30 10.2% 0.53[0.36,0.81]
Zhao 2013 24/36 30/34 15% 0.76[0.58,0.98]
Subtotal (95% CI) 113 115 38.06% 0.75[0.58,0.96]
Total events: 60 (Probiotic), 81 (No intervention)  
Heterogeneity: Tau2=0.02; Chi2=4.19, df=3(P=0.24); I2=28.32%  
Test for overall effect: Z=2.3(P=0.02)  
   
1.2.2 2 months  
Bajaj 2008 5/17 8/8 4.84% 0.32[0.16,0.66]
Bajaj 2014a 10/14 12/16 9.51% 0.95[0.62,1.47]
Sharma 2014 16/32 21/30 9.96% 0.71[0.47,1.09]
Subtotal (95% CI) 63 54 24.31% 0.65[0.38,1.1]
Total events: 31 (Probiotic), 41 (No intervention)  
Heterogeneity: Tau2=0.15; Chi2=6.55, df=2(P=0.04); I2=69.45%  
Test for overall effect: Z=1.62(P=0.11)  
   
1.2.3 3 months  
Vlachogiannakos 2014 14/35 30/33 9.92% 0.44[0.29,0.67]
Lunia 2014 20/42 34/39 12.28% 0.55[0.39,0.77]
Mittal 2009 26/40 36/40 15.44% 0.72[0.56,0.93]
Subtotal (95% CI) 117 112 37.63% 0.58[0.43,0.78]
Total events: 60 (Probiotic), 100 (No intervention)  
Heterogeneity: Tau2=0.04; Chi2=4.82, df=2(P=0.09); I2=58.54%  
Test for overall effect: Z=3.63(P=0)  
   
Total (95% CI) 293 281 100% 0.67[0.56,0.79]
Total events: 151 (Probiotic), 222 (No intervention)  
Heterogeneity: Tau2=0.04; Chi2=17.48, df=9(P=0.04); I2=48.5%  
Test for overall effect: Z=4.49(P<0.0001)  
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Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for subgroup differences: Chi2=1.68, df=1 (P=0.43), I2=0%  
Favours probiotic 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.3.   Comparison 1 Probiotic versus placebo or no intervention, Outcome 3 Adverse events.
Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Overt hepatic encephalopathy  
Liu 2004 0/20 0/20   Not estimable
Bajaj 2014a 0/18 0/19   Not estimable
Shavakhi 2014 0/23 1/23 3.4% 0.33[0.01,7.78]
Bajaj 2008 0/17 2/8 3.94% 0.1[0.01,1.87]
Vlachogiannakos 2014 0/37 6/35 4.19% 0.07[0,1.25]
Ziada 2013 1/30 5/30 7.76% 0.2[0.02,1.61]
Mittal 2009 2/40 4/40 12.56% 0.5[0.1,2.58]
Zhao 2013 2/40 7/40 14.83% 0.29[0.06,1.29]
Qiao 2010 2/32 12/32 16.89% 0.17[0.04,0.69]
Lunia 2014 5/42 11/39 36.42% 0.42[0.16,1.11]
Subtotal (95% CI) 299 286 100% 0.29[0.16,0.51]
Total events: 12 (Probiotic), 48 (No intervention)  
Heterogeneity: Tau2=0; Chi2=3.26, df=7(P=0.86); I2=0%  
Test for overall effect: Z=4.22(P<0.0001)  
   
1.3.2 Infection  
Bajaj 2014a 0/18 0/19   Not estimable
Subtotal (95% CI) 18 19 Not estimable
Total events: 0 (Probiotic), 0 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.3.3 Hospitalisation  
Bajaj 2014a 0/18 0/19   Not estimable
Shavakhi 2014 1/23 1/23 43.12% 1[0.07,15.04]
Mittal 2009 1/40 2/40 56.88% 0.5[0.05,5.3]
Subtotal (95% CI) 81 82 100% 0.67[0.11,4]
Total events: 2 (Probiotic), 3 (No intervention)  
Heterogeneity: Tau2=0; Chi2=0.14, df=1(P=0.71); I2=0%  
Test for overall effect: Z=0.43(P=0.66)  
   
1.3.4 Intolerance leading to discontinuation  
Bajaj 2014a 0/18 0/19   Not estimable
Subtotal (95% CI) 18 19 Not estimable
Total events: 0 (Probiotic), 0 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.3.5 Change of/or withdrawal from treatment  
Bajaj 2008 3/17 0/8 2.13% 3.5[0.2,60.7]
Shavakhi 2014 4/23 2/23 6.51% 2[0.41,9.87]
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Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Mittal 2009 3/40 3/40 6.96% 1[0.21,4.66]
Vlachogiannakos 2014 2/37 8/35 7.5% 0.24[0.05,1.04]
Bajaj 2014a 4/18 3/19 8.85% 1.41[0.36,5.43]
Sharma 2008 5/35 4/35 10.51% 1.25[0.37,4.27]
Ziada 2013 4/30 5/30 10.74% 0.8[0.24,2.69]
Zhao 2013 6/40 13/40 19.21% 0.46[0.19,1.09]
Lunia 2014 9/42 17/39 27.59% 0.49[0.25,0.97]
Subtotal (95% CI) 282 269 100% 0.7[0.46,1.07]
Total events: 40 (Probiotic), 55 (No intervention)  
Heterogeneity: Tau2=0.05; Chi2=9.01, df=8(P=0.34); I2=11.17%  
Test for overall effect: Z=1.63(P=0.1)  
Test for subgroup differences: Chi2=6.14, df=1 (P=0.05), I2=67.42%  
Favours probiotic 10000.001 100.1 1 Favours control
 
 
Analysis 1.4.   Comparison 1 Probiotic versus placebo or no intervention, Outcome 4 Quality of life.
Study or subgroup Probiotic No intervention Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.4.1 SF-36 Physical  
Bajaj 2008 14 -39 (5) 6 -39 (6) 100% 0[-5.47,5.47]
Subtotal *** 14   6   100% 0[-5.47,5.47]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.4.2 SF-36 Mental  
Bajaj 2008 14 -46 (3) 6 -42 (7) 100% -4[-9.82,1.82]
Subtotal *** 14   6   100% -4[-9.82,1.82]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.35(P=0.18)  
   
1.4.3 Change in Total SIP Score  
Bajaj 2014a 14 0.4 (7) 16 1.2 (6.7) 34.99% -0.81[-5.74,4.12]
Mittal 2009 34 -6.2 (3.4) 31 -1 (2.6) 65.01% -5.19[-6.65,-3.73]
Subtotal *** 48   47   100% -3.66[-7.75,0.44]
Heterogeneity: Tau2=6.16; Chi2=2.79, df=1(P=0.09); I2=64.17%  
Test for overall effect: Z=1.75(P=0.08)  
   
1.4.4 Change in SIP Psychological Score  
Bajaj 2014a 14 1.1 (9.5) 16 4.2 (8.6) 4.67% -3.07[-9.61,3.47]
Mittal 2009 34 -4.7 (3.5) 31 -1.1 (2.4) 95.33% -3.56[-5.01,-2.11]
Subtotal *** 48   47   100% -3.54[-4.95,-2.12]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=4.9(P<0.0001)  
   
1.4.5 Change in SIP Physical Score  
Bajaj 2014a 14 0 (5) 16 1.1 (5.3) 14.86% -1.11[-4.78,2.56]
Mittal 2009 34 -3.2 (2.1) 31 0.1 (2) 85.14% -3.26[-4.26,-2.26]
Subtotal *** 48   47   100% -2.94[-4.44,-1.44]
Heterogeneity: Tau2=0.43; Chi2=1.23, df=1(P=0.27); I2=18.52%  
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Study or subgroup Probiotic No intervention Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=3.85(P=0)  
Favours probiotic 105-10 -5 0 Favours control
 
 
Analysis 1.5.   Comparison 1 Probiotic versus placebo or no intervention,
Outcome 5 Plasma ammonia concentration (final and change scores) (μmol/L).
Study or subgroup Probiotic No intervention Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.5.1 1 month  
Sharma 2008 30 68.7 (28.4) 31 69.3 (33.3) 5.81% -0.6[-16.11,14.91]
Ziada 2013 26 52.5 (21.7) 25 74.5 (23.3) 7.38% -22.07[-34.45,-9.69]
Malaguarnera 2010 63 66.2 (28.8) 62 71.5 (29.8) 8.67% -5.25[-15.53,5.03]
Zhao 2013 40 72.9 (15.8) 40 76.4 (10.2) 11.72% -3.48[-9.32,2.36]
Liu 2004 20 38.6 (3.9) 20 41.5 (5.2) 13.44% -2.9[-5.75,-0.05]
Subtotal *** 179   178   47.02% -5.55[-10.67,-0.42]
Heterogeneity: Tau2=16.49; Chi2=9, df=4(P=0.06); I2=55.54%  
Test for overall effect: Z=2.12(P=0.03)  
   
1.5.2 2 months  
Pereg 2011 18 42.1 (26.9) 18 45.2 (23.6) 5.38% -3.1[-19.63,13.43]
Bajaj 2008 14 50 (26) 6 40 (3) 6.61% 10[-3.83,23.83]
Bajaj 2014a 14 29.3 (13.7) 16 43.4 (19.7) 7.59% -14.1[-26.13,-2.07]
Malaguarnera 2010 63 55.9 (15.5) 62 65.3 (22.3) 11.1% -9.35[-16.09,-2.61]
Subtotal *** 109   102   30.67% -5.11[-14.56,4.34]
Heterogeneity: Tau2=55.43; Chi2=7.82, df=3(P=0.05); I2=61.65%  
Test for overall effect: Z=1.06(P=0.29)  
   
1.5.3 3 months  
Mittal 2009 37 -7.3 (7.9) 36 -0.5 (7.8) 13.08% -6.79[-10.39,-3.19]
Subtotal *** 37   36   13.08% -6.79[-10.39,-3.19]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.7(P=0)  
   
1.5.4 6 months  
Qiao 2010 32 43.8 (17.6) 32 74.8 (20.8) 9.23% -31.08[-40.5,-21.66]
Subtotal *** 32   32   9.23% -31.08[-40.5,-21.66]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=6.46(P<0.0001)  
   
Total *** 357   348   100% -8.29[-13.17,-3.41]
Heterogeneity: Tau2=43.98; Chi2=47.57, df=10(P<0.0001); I2=78.98%  
Test for overall effect: Z=3.33(P=0)  
Test for subgroup differences: Chi2=24.67, df=1 (P<0.0001), I2=87.84%  
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Comparison 2.   Probiotic versus lactulose
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 All-cause mortality 2 200 Risk Ratio (M-H, Random, 95%
CI)
5.00 [0.25, 102.00]
1.1 1 month 1 80 Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
1.2 2 months 1 120 Risk Ratio (M-H, Random, 95%
CI)
5.00 [0.25, 102.00]
2 No recovery (incomplete resolution of
clinical symptoms)
7 430 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.85, 1.21]
2.1 1 month or less 5 255 Risk Ratio (M-H, Random, 95%
CI)
0.94 [0.75, 1.20]
2.2 2 months 1 95 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.65, 1.47]
2.3 3 months 1 80 Risk Ratio (M-H, Random, 95%
CI)
1.24 [0.85, 1.80]
3 Adverse events 7   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
3.1 Overt hepatic encephalopathy 6 420 Risk Ratio (M-H, Random, 95%
CI)
1.17 [0.63, 2.17]
3.2 Infection 0 0 Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
3.3 Hospitalisation 1 80 Risk Ratio (M-H, Random, 95%
CI)
0.33 [0.04, 3.07]
3.4 Intolerance leading to discontinuation 3 220 Risk Ratio (M-H, Random, 95%
CI)
0.35 [0.08, 1.43]
3.5 Change of/or withdrawal from treat-
ment
7 490 Risk Ratio (M-H, Random, 95%
CI)
1.27 [0.88, 1.82]
4 Health-related quality of life 1   Mean Difference (IV, Random,
95% CI)
Subtotals only
4.1 Change in Total SIP Score 1 69 Mean Difference (IV, Random,
95% CI)
0.65 [-1.13, 2.43]
4.2 Change in SIP Psychological Score 1 69 Mean Difference (IV, Random,
95% CI)
0.48 [-1.04, 2.00]
4.3 Change in SIP Physical Score 1 69 Mean Difference (IV, Random,
95% CI)
0.38 [-0.61, 1.37]
5 Plasma ammonia concentration (final
and change scores) (μmol/L)
6 325 Mean Difference (IV, Random,
95% CI)
-2.93 [-9.36, 3.50]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
5.1 1 month or less 5 248 Mean Difference (IV, Random,
95% CI)
-4.30 [-13.17, 4.56]
5.2 3 months 1 77 Mean Difference (IV, Random,
95% CI)
1.16 [-1.96, 4.28]
 
 
Analysis 2.1.   Comparison 2 Probiotic versus lactulose, Outcome 1 All-cause mortality.
Study or subgroup Probiotic Lactulose Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.1.1 1 month  
Zhao 2013 0/40 0/40   Not estimable
Subtotal (95% CI) 40 40 Not estimable
Total events: 0 (Probiotic), 0 (Lactulose)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.1.2 2 months  
Mouli 2014 2/60 0/60 100% 5[0.25,102]
Subtotal (95% CI) 60 60 100% 5[0.25,102]
Total events: 2 (Probiotic), 0 (Lactulose)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.3)  
   
Total (95% CI) 100 100 100% 5[0.25,102]
Total events: 2 (Probiotic), 0 (Lactulose)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.3)  
Test for subgroup differences: Not applicable  
Favours probiotic 2000.005 100.1 1 Favours lactulose
 
 
Analysis 2.2.   Comparison 2 Probiotic versus lactulose, Outcome
2 No recovery (incomplete resolution of clinical symptoms).
Study or subgroup Probiotic Lactulose Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.2.1 1 month or less  
Loguercio 1995 3/18 8/19 2.37% 0.4[0.12,1.26]
Loguercio 1987 6/16 9/15 5.58% 0.63[0.29,1.33]
Ziada 2013 13/27 13/26 10.59% 0.96[0.56,1.67]
Sharma 2008 15/31 14/31 11.27% 1.07[0.63,1.82]
Zhao 2013 24/36 23/36 28.03% 1.04[0.74,1.46]
Subtotal (95% CI) 128 127 57.83% 0.94[0.75,1.2]
Total events: 61 (Probiotic), 67 (Lactulose)  
Heterogeneity: Tau2=0; Chi2=4.03, df=4(P=0.4); I2=0.66%  
Favours probiotic 100.1 50.2 20.5 1 Favours lactulose
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Study or subgroup Probiotic Lactulose Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.47(P=0.64)  
   
2.2.2 2 months  
Mouli 2014 22/45 25/50 19.18% 0.98[0.65,1.47]
Subtotal (95% CI) 45 50 19.18% 0.98[0.65,1.47]
Total events: 22 (Probiotic), 25 (Lactulose)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.11(P=0.91)  
   
2.2.3 3 months  
Mittal 2009 26/40 21/40 22.98% 1.24[0.85,1.8]
Subtotal (95% CI) 40 40 22.98% 1.24[0.85,1.8]
Total events: 26 (Probiotic), 21 (Lactulose)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.12(P=0.26)  
   
Total (95% CI) 213 217 100% 1.01[0.85,1.21]
Total events: 109 (Probiotic), 113 (Lactulose)  
Heterogeneity: Tau2=0; Chi2=5.47, df=6(P=0.49); I2=0%  
Test for overall effect: Z=0.14(P=0.89)  
Test for subgroup differences: Chi2=1.48, df=1 (P=0.48), I2=0%  
Favours probiotic 100.1 50.2 20.5 1 Favours lactulose
 
 
Analysis 2.3.   Comparison 2 Probiotic versus lactulose, Outcome 3 Adverse events.
Study or subgroup Probiotic Lactulose Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 Overt hepatic encephalopathy  
Zhao 2013 2/40 1/40 6.78% 2[0.19,21.18]
Mittal 2009 2/40 1/40 6.78% 2[0.19,21.18]
Ziada 2013 1/30 2/30 6.86% 0.5[0.05,5.22]
Loguercio 1987 1/20 2/20 7.02% 0.5[0.05,5.08]
Loguercio 1995 2/21 1/19 7.02% 1.81[0.18,18.39]
Mouli 2014 12/60 10/60 65.54% 1.2[0.56,2.56]
Subtotal (95% CI) 211 209 100% 1.17[0.63,2.17]
Total events: 20 (Probiotic), 17 (Lactulose)  
Heterogeneity: Tau2=0; Chi2=1.56, df=5(P=0.91); I2=0%  
Test for overall effect: Z=0.51(P=0.61)  
   
2.3.2 Infection  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Probiotic), 0 (Lactulose)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.3.3 Hospitalisation  
Mittal 2009 1/40 3/40 100% 0.33[0.04,3.07]
Subtotal (95% CI) 40 40 100% 0.33[0.04,3.07]
Total events: 1 (Probiotic), 3 (Lactulose)  
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Study or subgroup Probiotic Lactulose Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.97(P=0.33)  
   
2.3.4 Intolerance leading to discontinuation  
Ziada 2013 0/30 2/30 22.4% 0.2[0.01,4]
Loguercio 1987 1/20 2/20 37.36% 0.5[0.05,5.08]
Mouli 2014 1/60 3/60 40.24% 0.33[0.04,3.11]
Subtotal (95% CI) 110 110 100% 0.35[0.08,1.43]
Total events: 2 (Probiotic), 7 (Lactulose)  
Heterogeneity: Tau2=0; Chi2=0.23, df=2(P=0.89); I2=0%  
Test for overall effect: Z=1.47(P=0.14)  
   
2.3.5 Change of/or withdrawal from treatment  
Loguercio 1987 1/20 2/20 2.44% 0.5[0.05,5.08]
Mittal 2009 3/40 1/40 2.66% 3[0.33,27.63]
Loguercio 1995 6/21 1/19 3.2% 5.43[0.72,41.09]
Sharma 2008 4/35 4/35 7.7% 1[0.27,3.69]
Ziada 2013 4/30 6/30 9.74% 0.67[0.21,2.13]
Zhao 2013 6/40 5/40 10.77% 1.2[0.4,3.62]
Mouli 2014 27/60 20/60 63.5% 1.35[0.86,2.13]
Subtotal (95% CI) 246 244 100% 1.27[0.88,1.82]
Total events: 51 (Probiotic), 39 (Lactulose)  
Heterogeneity: Tau2=0; Chi2=4.59, df=6(P=0.6); I2=0%  
Test for overall effect: Z=1.28(P=0.2)  
Test for subgroup differences: Chi2=4.23, df=1 (P=0.24), I2=29.15%  
Favours probiotic 1000.01 100.1 1 Favours lactulose
 
 
Analysis 2.4.   Comparison 2 Probiotic versus lactulose, Outcome 4 Health-related quality of life.
Study or subgroup Probiotic Lactulose Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.4.1 Change in Total SIP Score  
Mittal 2009 34 -6.2 (3.4) 35 -6.9 (4.1) 100% 0.65[-1.13,2.43]
Subtotal *** 34   35   100% 0.65[-1.13,2.43]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.72(P=0.47)  
   
2.4.2 Change in SIP Psychological Score  
Mittal 2009 34 -4.7 (3.5) 35 -5.2 (2.9) 100% 0.48[-1.04,2]
Subtotal *** 34   35   100% 0.48[-1.04,2]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.62(P=0.54)  
   
2.4.3 Change in SIP Physical Score  
Mittal 2009 34 -3.2 (2.1) 35 -3.6 (2.1) 100% 0.38[-0.61,1.37]
Subtotal *** 34   35   100% 0.38[-0.61,1.37]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.75(P=0.45)  
Test for subgroup differences: Chi2=0.07, df=1 (P=0.97), I2=0%  
Favours probiotic 42-4 -2 0 Favours lactulose
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Analysis 2.5.   Comparison 2 Probiotic versus lactulose, Outcome 5
Plasma ammonia concentration (final and change scores) (μmol/L).
Study or subgroup Probiotic Lactulose Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.5.1 1 month or less  
Sharma 2008 31 75.7 (33) 31 69.3 (33.3) 9.93% 6.4[-10.1,22.9]
Loguercio 1995 14 57.3 (19.8) 11 62.7 (17.3) 11.62% -5.4[-19.96,9.16]
Ziada 2013 26 52.5 (21.7) 24 55.6 (28.1) 12.17% -3.17[-17.17,10.83]
Loguercio 1987 16 58.7 (5.9) 15 76.3 (17.6) 17.87% -17.61[-26.98,-8.24]
Zhao 2013 40 72.9 (15.8) 40 71.6 (16.2) 21.44% 1.31[-5.7,8.32]
Subtotal *** 127   121   73.03% -4.3[-13.17,4.56]
Heterogeneity: Tau2=64.38; Chi2=11.87, df=4(P=0.02); I2=66.3%  
Test for overall effect: Z=0.95(P=0.34)  
   
2.5.2 3 months  
Mittal 2009 37 -7.3 (7.9) 40 -8.5 (5.8) 26.97% 1.16[-1.96,4.28]
Subtotal *** 37   40   26.97% 1.16[-1.96,4.28]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.73(P=0.47)  
   
Total *** 164   161   100% -2.93[-9.36,3.5]
Heterogeneity: Tau2=37.34; Chi2=15.4, df=5(P=0.01); I2=67.54%  
Test for overall effect: Z=0.89(P=0.37)  
Test for subgroup differences: Chi2=1.3, df=1 (P=0.25), I2=22.96%  
Favours probiotic 5025-50 -25 0 Favours lactulose
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Study Probiotics used
Bajaj 2008 Streptococcus thermophilus,Lactobacillus bulgaricus,Lactobacillus acidophilus,Lactobacillus ca-
sei,Bifidobacteria
Bajaj 2014a Lactobacillus GG AT strain 53103
Dhiman 2013a VSL#3 (containing Bifidobacterium breve,Bifidobacterium longum,Bifidobacterium infantis,Lac-
tobacillus acidophilus,Lactobacillus plantarum,Lactobacillus paracasei,Lactobacillus bulgaricus,
Streptococcus thermophilus)
Liu 2004 Pediacoccus pentosaceus,Leuconostoc mesenteroides,Lactobacillus paracasei,Lactobacillus plan-
tarum
Loguercio 1987 Enterococcus lactic acid bacteria strain SF68
Loguercio 1995 Enterococcus faecium strain SF68
Lunia 2014 VSL#3 (containing Streptococcus thermophilus,Bifidobacterium breve,Bifidobacterium longum,B-
ifidobacterium infantis,Lactobacillus acidophilus,Lactobacillus plantarum,Lactobacillus paraca-
sei,Lactobacillus bulgaricus)
Table 1.   Types of probiotics used across studies 
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Malaguarnera 2010 Bifidobacterium (subtype not available)
Mittal 2009 VSL#3 (containing Streptococcus thermophilus,Bifidobacterium breve,Bifidobacterium longum,B-
ifidobacterium infantis,Lactobacillus acidophilus,Lactobacillus plantarum,Lactobacillus paraca-
sei,Lactobacillus bulgaricus)
Mouli 2014 VSL#3 (4 strains of Lactobacillus (L acidophilus DSM 24735, L plantarum DSM 24730, L paracasei
DSM 24733, L delbrueckii subsp. bulgaricus DSM 24734), 3 strains of Bifidobacterium (B longum DSM
24736, B breve DSM 24732, B infantis DSM 24737), and 1 strain of Streptococcus (S thermophilus DSM
24731))
Nair 2008 Lactobacillus acidophilus,Lactobacillus rhamnosus,Bifidobacterium longum,Saccharomyces
boulardii
Pereg 2011 Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium bifidum, Streptococcus ther-
mophilus (Bio Plus, Supherb, Israel)
Qiao 2010 Bifid triple viable (not further specified)
Saji 2011 Lactobacillus acidophilus,Lactobacillus rhamnosus,Bifidobacterium longum,Saccharomyces
boulardii
Sharma 2008 Enterococcus faecalis,Clostridium butyricum,Bacillus mesentricus, lactic acid Bacillus
Sharma 2014 Velgut ERIS Pharmaceuticals, Ahmadabad, India (Lactobacillus acidophilus,Lactobacillus rhamno-
sus,Lactobacillus plantarum,Lactobacillus casei,Bifidobacterium longum,Bifidobacterium infantis,Bi-
fidobacterium breve,Saccharomyces boulardii,Streptococcus thermophilus)
Shavakhi 2014 Balance (Protexin Co., Somerset, UK) Lactobacillus strains (L casei,L rhamnosus,L acidophilus,L bul-
garicus),Bifidobacterium strains (B breve, B longum), andStreptococcus thermophilus
Vlachogiannakos 2014 Lactobacillus plantarum 299v
Zhao 2013 Unclear
Zhitai 2013 Live Bacillus cereus capsules
Ziada 2013 Lactobacillus acidophilus
Table 1.   Types of probiotics used across studies  (Continued)
 
 
Probiotic versus placebo or no intervention
No-recovery Studies Partici-
pants
Effect estimate
Risk ratio [95% CI]
Differ-
ence P
Type of probiotic 10 574 — 0.69
Lactobacillus 4 195 0.67 [0.45, 1.00] —
Mixed 5 309 0.65 [0.50, 0.83] —
Unclear 1 70 0.76 [0.58, 0.98] —
Table 2.   Heterogeneity subgroup analysis 
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Grade of hepatic encephalopathy 10 574 — 0.06
Minimal 8 473 0.63 [0.52, 0.76] —
Overt 2 101 0.98 [0.64, 1.48] —
Duration of therapy 10 574 — 0.43
<= 1 month 4 228 0.75 [0.58, 0.96] —
1 > 2 months 3 117 0.65 [0.38, 1.10] —
2 + months 3 229 0.58 [0.43, 0.78] —
Co-interventions 10 574 — 0.17
No treatment 8 473 0.63 [0.52, 0.76] —
Bioactive fermentable fibre 1 40 1.00 [0.54, 1.86] —
Lactulose 1 61 0.96 [0.55, 1.69] —
Plasma ammonia concentration Studies Partici-
pants
Effect estimate
Mean difference [95% CI]
Differ-
ence P
Type of probiotic 10 580 — 0.35
Bifidobacterium 1 125 -9.35 [-16.09, -2.61] —
Lactobacillus 3 121 -11.90 [-24.41, 0.60] —
Mixed 4 190 -1.80 [-9.65, 6.06] —
Unclear 2 144 -17.02 [-44.07, 10.02] —
Grade of hepatic encephalopathy 10 580 — 0.85
Minimal 9 455 -8.50 [-14.38, -2.62] —
Overt 1 125 -9.35 [-16.09, -2.61] —
Duration of therapy 10 580 — 0.58
<=1 month 4 232 -5.93 [-12.25, 0.39] —
1 > 2 months 4 211 -5.11 [-14.56, 4.34] —
2 + months 2 137 -18.53 [-42.32, 5.26] —
Co-interventions used 10 580 — 0.11
No treatment 7 354 -10.42 [-18.68, -2.17] —
Bioactive fermentable fibre 1 40 -2.90 [-5.51, -0.29] —
Table 2.   Heterogeneity subgroup analysis  (Continued)
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Lactulose 2 186 -7.88 [-14.29, -1.47] —
Probiotic versus lactulose
Plasma ammonia concentration Studies Partici-
pants
Effect estimate
Mean difference [95% CI]
Differ-
ence P
Type of probiotic 6 325 — 0.13
Enterococcus SF68 2 56 -12.83 [-24.51, -1.15] —
Mixed 2 139 1.34 [-1.72, 4.40] —
Lactobacillus 1 50 -3.17 [-17.17, 10.83] —
Unclear 1 80 1.31 [-5.70, 8.32] —
Grade of hepatic encephalopathy 6 325 — 0.02
Minimal 4 269 1.16 [-1.59, 3.91] —
Overt 2 56 -12.83 [-24.51, -1.15] —
Table 2.   Heterogeneity subgroup analysis  (Continued)
CI: confidence interval
 
 
A P P E N D I C E S
Appendix 1. Search strategies
 
Database Span of search Search strategy
The Cochrane He-
pato-Biliary Group
Controlled Trials
Register
August 2015 (probiot* OR lactobacil* OR bifidobacter*) AND ('hepatic encephalopath*' OR (liver AND
(diseas* OR cirrhosis*)))
Cochrane Cen-
tral Register of
Controlled Trials
(CENTRAL) in the
Cochrane Library
2016, Issue 5. #1 LIVER CIRRHOSIS explode all trees (MeSH)
#2 (liver cirrhosis):ti,ab,kw
#3 HEPATIC ENCEPHALOPATHY explode all trees (MeSH)
#4 (hepatic encephalopathy):ti,ab,kw
#5 (liver next cirrhosis)
#6 (hepatic next encephalopathy)
#7 (#1 or #2 or #3 or #4 or #5 or #6)
#8 probiotics explode all trees (MeSH)
#9 (probiotics):ti,ab,kw
#10 lactobacillus explode all trees (MeSH)
#11 (lactobacillus):ti,kw,ab
#12 bifidobacterium explode all trees (MeSH)
#13 (bifidobacterium):ti,kw,ab
#14 (#8 or #9 or #10 or #11 or #12 or #13)
#15 (#7 and #14)
MEDLINE Ovid 1946 to June 2016. #1 randomised controlled trial.pt. [#1 randomized controlled trial.pt. in 2015 update]
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#2 controlled clinical trial.pt.
#3 randomized.ab.
#4 placebo.ab.
#5 drug therapy.fs.
#6 randomly.ab.
#7 trial.ab.
#8 groups.ab.
#9 or/1-8
#10 animals.sh.
#11 9 not 10
#12 exp hepatic encephalopathy/
#13 hepatic encephalopathy.tw
#14 exp liver cirrhosis/
#15 liver cirrhosis.tw
#16 12 or 13 or 14 or 15
#17 exp probiotics/
#18 probiotic.tw
#19 exp lactobacillus/
#20 lactobacillus.tw
#21 exp bifidobacterium/
#22 bifidobacterium.tw
#23 17 or 18 or 19 or 20 or 21 or 22
#24 11 and 16 and 23
Embase Ovid 1974 to June 2016. #1 random:.tw.
#2 clinical trial:.mp.
#3 exp health care quality/
#4 1 or 2 or 3
#5 exp hepatic encephalopathy/
#6 hepatic encephalopathy.tw
#7 exp liver cirrhosis/
#8 liver cirrhosis.tw
#9 5 or 6 or 7 or 8
#10 exp probiotics/
#11 probiotic.tw
#12 exp lactobacillus/
#13 lactobacillus.tw
#14 exp bifidobacterium/
#15 bifidobacterium.tw
#16 10 or 11 or 12 or 13 or 14 or 15
#17 4 and 9 and 16
Science Citation
Index Expanded
(Web of Science)
1900 to June 2016. # 1 TS=(probiotic OR probiot* OR lactobacil* OR bifidobacter*)
# 2 TS=(hepatic encephalopath* OR liver diseas*)
# 3 #1 AND #2
# 4 TS=(random* OR blind* OR placebo*)
# 5 #3 AND #4
  (Continued)
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F E E D B A C K
Comment on an intervention in the 'Probiotics for people with hepatic encephalopathy' review, published 23
February 2017. Comment submitted, 16 July 2019
Summary
The randomised clinical trials included in the systematic review assessed a probiotic formulation know at the time of the conduct of the
trials as VSL#3. This probiotic formulation has been renamed the ‘De Simione Formulation’ (DSF) aTer me, as I invented it. The De Simone
Formulation is available under the brand names Visbiome® and Vivomixx®. To the best of my knowledge, current products known as VSL#3
have not been assessed in people with inflammatory bowel disease, irritable bowel disease, or liver diseases. The current products known
as VSL#3 are not the same formulation as the original product I invented.
I hereby ask you to bring this notice as well as to update your review accordingly.
Yours sincerely,
Professor Claudio De Simone, Switzerland
claudio.desimone@bluewin.ch
Conflicts of interest: I am the inventor of ‘De Simione Formulation’ (DSF).
Comment submitted 16.07.2019
Reply
Dear Professor Claudio De Simone,
In this review, ‘VSL#3’ refers only to the product used in the cited literature, independent from present product labelling. Since the time
our literature searches were performed, this product is now known by the generic name ‘De Simone Formulation" (See Reference*).
Yours sincerely,
Richard G McGee and co-authors
_______________________
*Reference: De Simone C. Letter: what gastroenterologists should know about VSL#3. Alimentary Pharmacology & Therapeutics. 2018
Mar;47(5):698-9 (onlinelibrary.wiley.com/doi/full/10.1111/apt.14515).
Reply submitted 20.07.2019
Contributors
Submitter of the comment: Claudio De Simone, Switzerland
Submitter of the reply: Richard G McGee, Australia, on behalf of the review authors
W H A T ' S   N E W
 
Date Event Description
24 July 2019 Amended Feedback received and reply to comment provided
 
H I S T O R Y
Protocol first published: Issue 9, 2010
Review first published: Issue 11, 2011
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Date Event Description
14 June 2016 New search has been performed June 2016 search update: Seven new trials added. The review is
now based on 21 trials with a total of 1420 participants.
14 June 2016 New citation required and conclusions
have changed
The conclusions changed from “While probiotics appear to re-
duce plasma ammonia concentration when compared with
placebo or no intervention, we are unable to conclude that
probiotics are efficacious in altering clinically relevant out-
comes” (McGee 2011), to “Overall, probiotics appear to help
symptom resolution, reduce plasma ammonia concentrations,
and result in less overt hepatic encephalopathy compared with
no treatment, although we consider the evidence to be of low
quality”.
 
C O N T R I B U T I O N S   O F   A U T H O R S
RD: participated in all stages of the review.
RMG: conceived the review, designed the protocol, and participated in all stages of the review.
SMR: draTed the protocol, contributed to the search, provided content area advice, and reviewed the manuscript.
ACW: draTed the protocol, provided methodological advice, contributed to study design, and reviewed the manuscript.
D E C L A R A T I O N S   O F   I N T E R E S T
RD: is a recipient of a scholarship from The University of Sydney. This scholarship had no influence on the conduct of this review.
RMG: none to declare.
SMR: is an author of a trial included in the review. SMR had no influence on its inclusion or data extraction and analysis.
ACW: none to declare.
S O U R C E S   O F   S U P P O R T
Internal sources• No financial support was received for the conduct of this review, Australia.
External sources• No financial support was received for the conduct of this review, Australia.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
The following changes have been made in the update.
• The search terms used have been updated to keep the search strategy up to date.• The outcome adverse events, which previously reported “number of adverse events”, has been expanded to include overt hepatic
encephalopathy, infections, hospitalisations, intolerance leading to discontinuation, and change of/or withdrawal from treatment.• The previous outcome “change of/or withdrawal from treatment” is now a subgroup of adverse events.• Final and change scores have been combined into the same analysis for plasma ammonia concentration.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Cause of Death;  Gastrointestinal Agents  [*therapeutic use];  Hepatic Encephalopathy  [mortality]  [*therapy];  Lactulose  [*therapeutic
use];  Probiotics  [*therapeutic use];  Quality of Life;  Randomized Controlled Trials as Topic
MeSH check words
Humans
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